Aberrant	O
splicing	O
of	O
the	O
TSG101	B-DNA
and	I-DNA
FHIT	I-DNA
genes	I-DNA
occurs	O
frequently	O
in	O
multiple	O
malignancies	O
and	O
in	O
normal	O
tissues	O
and	O
mimics	O
alterations	O
previously	O
described	O
in	O
tumours	O
.	O

Intragenic	O
deletions	O
of	O
TSG101	B-DNA
,	O
the	O
human	O
homolog	O
of	O
a	O
mouse	B-DNA
gene	I-DNA
(	O
tsg101	B-DNA
)	O
that	O
acts	O
to	O
suppress	O
malignant	O
cell	O
growth	O
,	O
were	O
reported	O
in	O
human	B-cell_type
breast	I-cell_type
tumours	I-cell_type
.	O

We	O
screened	O
TSG101	B-DNA
for	O
somatic	O
mutations	O
in	O
DNA	O
and	O
RNA	O
samples	O
isolated	O
from	O
a	O
variety	O
of	O
common	O
human	O
malignancies	O
,	O
EBV-immortalised	B-cell_type
B-cells	I-cell_type
,	O
and	O
normal	O
lung	O
parenchyma	O
.	O

Intragenic	O
TSG101	B-DNA
deletions	O
in	O
RNA	B-RNA
transcripts	I-RNA
were	O
frequently	O
found	O
in	O
all	O
types	O
of	O
samples	O
.	O

Analysis	O
of	O
DNA	O
failed	O
to	O
show	O
genomic	O
rearrangements	O
corresponding	O
to	O
transcripts	O
containing	O
deletions	O
in	O
the	O
same	O
samples	O
.	O

The	O
breakpoints	O
of	O
most	O
transcript	O
deletions	O
coincide	O
with	O
genuine	O
or	O
cryptic	O
splice	B-DNA
site	I-DNA
sequences	I-DNA
,	O
suggesting	O
that	O
they	O
result	O
from	O
alternative	O
or	O
aberrant	O
splicing	O
.	O

A	O
similar	O
spectrum	O
of	O
transcript	O
deletions	O
has	O
previously	O
been	O
described	O
in	O
the	O
putative	B-DNA
tumour	I-DNA
suppressor	I-DNA
gene	I-DNA
FHIT	B-DNA
.	O

We	O
analysed	O
FHIT	B-DNA
in	O
the	O
same	O
series	O
of	O
RNA	B-RNA
samples	I-RNA
and	O
detected	O
truncated	O
FHIT	B-RNA
transcripts	I-RNA
frequently	O
in	O
both	O
tumour	O
and	O
normal	O
tissues	O
.	O

In	O
addition	O
,	O
transcripts	O
from	O
TSG101	B-DNA
,	O
FHIT	B-DNA
and	O
seven	O
other	O
genes	O
were	O
analysed	O
in	O
RNA	O
isolated	O
from	O
normal	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
.	O

Large	O
TSG101	B-DNA
and	O
FHIT	B-DNA
intragenic	O
transcript	O
deletions	O
were	O
detected	O
and	O
these	O
appeared	O
to	O
be	O
the	O
predominant	O
transcript	O
in	O
'aged	B-cell_type
'	I-cell_type
lymphocytes	I-cell_type
.	O

Similar	O
alterations	O
were	O
not	O
detected	O
in	O
transcripts	O
of	O
the	O
other	O
genes	O
which	O
were	O
analysed	O
.	O

Our	O
findings	O
demonstrate	O
that	O
truncated	B-RNA
TSG101	I-RNA
and	I-RNA
FHIT	I-RNA
transcripts	I-RNA
are	O
commonly	O
detected	O
in	O
both	O
normal	O
and	O
malignant	O
tissues	O
and	O
that	O
a	O
significant	O
fraction	O
of	O
these	O
are	O
likely	O
to	O
be	O
the	O
result	O
of	O
aberrant	O
splicing	O
.	O

While	O
we	O
can	O
not	O
exclude	O
that	O
alterations	O
in	O
TSG101	B-DNA
and	O
FHIT	B-DNA
occur	O
during	O
cancer	O
development	O
,	O
our	O
data	O
indicate	O
that	O
in	O
this	O
context	O
the	O
commonly	O
observed	O
transcript	O
abnormalities	O
are	O
misleading	O
.	O

Oncogene	NULL
(	NULL
1997	NULL
)	NULL
15	NULL
,	NULL
2119-2126	NULL
©	NULL
1997	NULL
Stockton	NULL
Press	NULL
All	NULL
rights	NULL
reserved	NULL
0950-9232/97	NULL
$	NULL
12.00	NULL
Aberrant	NULL
splicing	NULL
of	NULL
the	NULL
TSG1I01	NULL
and	NULL
FHIT	NULL
genes	NULL
occurs	NULL
frequently	NULL
in	NULL
multiple	NULL
malignancies	NULL
and	NULL
in	NULL
normal	NULL
tissues	NULL
and	NULL
mimics	NULL
alterations	NULL
previously	NULL
described	NULL
in	NULL
tumours	NULL
Simon	NULL
A	NULL
Gayther*	NULL
``	NULL
,	NULL
Piotr	NULL
Barski*	NULL
``	NULL
,	NULL
Sarah	NULL
J	NULL
Batley	NULL
``	NULL
,	NULL
Limin	NULL
Li	NULL
,	NULL
Karen	NULL
AF	NULL
de	NULL
Foy	NULL
!	NULL

,	NULL
Stanley	NULL
N	NULL
Cohen**	NULL
,	NULL
Bruce	NULL
AJ	NULL
Ponder	NULL
``	NULL
and	NULL
Carlos	NULL
Caldas	NULL
'CRC	NULL
Human	NULL
Cancer	NULL
Genetics	NULL
Research	NULL
Group	NULL
,	NULL
Box	NULL
238	NULL
,	NULL
Addenbrooke	NULL
's	NULL
Hospital	NULL
,	NULL
Hills	NULL
Road	NULL
,	NULL
Cambridge	NULL
,	NULL
CB2	NULL
200	NULL
,	NULL
UK	NULL
;	NULL
``	NULL
CRC	NULL
Academic	NULL
Department	NULL
of	NULL
Oncology	NULL
,	NULL
University	NULL
of	NULL
Cambridge	NULL
School	NULL
of	NULL
Clinical	NULL
Medicine	NULL
,	NULL
Box	NULL
193	NULL
,	NULL
Addenbrooke	NULL
's	NULL
Hospital	NULL
,	NULL
Hills	NULL
Road	NULL
,	NULL
Cambridge	NULL
,	NULL
CB2	NULL
200	NULL
,	NULL
UK	NULL
;	NULL
*Department	NULL
of	NULL
Genetics	NULL
,	NULL
Stanford	NULL
University	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
Stanford	NULL
,	NULL
California	NULL
,	NULL
USA	NULL
;	NULL
*Department	NULL
of	NULL
Medicine	NULL
,	NULL
Stanford	NULL
University	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
Stanford	NULL
,	NULL
California	NULL
,	NULL
USA	NULL
Intragenic	NULL
deletions	NULL
of	NULL
TSGI01	NULL
,	NULL
the	NULL
human	NULL
homolog	NULL
of	NULL
a	NULL
mouse	NULL
gene	NULL
(	NULL
¢sg7017	NULL
)	NULL
that	NULL
acts	NULL
to	NULL
suppress	NULL
malignant	NULL
cell	NULL
growth	NULL
,	NULL
were	NULL
reported	NULL
in	NULL
human	NULL
breast	NULL
tumours	NULL
.	NULL

We	NULL
screened	NULL
TSGIO1	NULL
for	NULL
somatic	NULL
mutations	NULL
in	NULL
DNA	NULL
and	NULL
RNA	NULL
samples	NULL
isolated	NULL
from	NULL
a	NULL
variety	NULL
of	NULL
common	NULL
human	NULL
malignancies	NULL
,	NULL
EBV-immortalised	NULL
B-cells	NULL
,	NULL
and	NULL
normal	NULL
lung	NULL
parenchyma	NULL
.	NULL

Intragenic	NULL
TS8SGI01	NULL
deletions	NULL
in	NULL
RNA	NULL
transcripts	NULL
were	NULL
frequently	NULL
found	NULL
in	NULL
all	NULL
types	NULL
of	NULL
samples	NULL
.	NULL

Analysis	NULL
of	NULL
DNA	NULL
failed	NULL
to	NULL
show	NULL
genomic	NULL
rearrangements	NULL
corresponding	NULL
to	NULL
transcripts	NULL
containing	NULL
deletions	NULL
in	NULL
the	NULL
same	NULL
samples	NULL
.	NULL

The	NULL
breakpoints	NULL
of	NULL
most	NULL
transcript	NULL
deletions	NULL
coincide	NULL
with	NULL
genuine	NULL
or	NULL
cryptic	NULL
splice	NULL
site	NULL
sequences	NULL
,	NULL
suggesting	NULL
that	NULL
they	NULL
result	NULL
from	NULL
alternative	NULL
or	NULL
aberrant	NULL
splicing	NULL
.	NULL

A	NULL
similar	NULL
spectrum	NULL
of	NULL
transcript	NULL
deletions	NULL
has	NULL
previously	NULL
been	NULL
described	NULL
in	NULL
the	NULL
putative	NULL
tumour	NULL
suppressor	NULL
gene	NULL
FHZZT	NULL
.	NULL

We	NULL
analysed	NULL
FHZT	NULL
in	NULL
the	NULL
same	NULL
series	NULL
of	NULL
RNA	NULL
samples	NULL
and	NULL
detected	NULL
truncated	NULL
FHIT	NULL
transcripts	NULL
frequently	NULL
in	NULL
both	NULL
tumour	NULL
and	NULL
normal	NULL
tissues	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
transcripts	NULL
from	NULL
TSGI01	NULL
,	NULL
FHIT	NULL
and	NULL
seven	NULL
other	NULL
genes	NULL
were	NULL
analysed	NULL
in	NULL
RNA	NULL
isolated	NULL
from	NULL
normal	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
.	NULL

Large	NULL
TSGI0	NULL
!	NULL

and	NULL
FHIT	NULL
intragenic	NULL
transcript	NULL
deletions	NULL
were	NULL
detected	NULL
and	NULL
these	NULL
appeared	NULL
to	NULL
be	NULL
the	NULL
predominant	NULL
transcript	NULL
in	NULL
'aged	NULL
'	NULL
lymphocytes	NULL
.	NULL

Similar	NULL
alterations	NULL
were	NULL
not	NULL
detected	NULL
in	NULL
transcripts	NULL
of	NULL
the	NULL
other	NULL
genes	NULL
which	NULL
were	NULL
analysed	NULL
.	NULL

Our	NULL
findings	NULL
demonstrate	NULL
that	NULL
truncated	NULL
TSGI01	NULL
and	NULL
FHIT	NULL
transcripts	NULL
are	NULL
commonly	NULL
detected	NULL
in	NULL
both	NULL
normal	NULL
and	NULL
malignant	NULL
tissues	NULL
and	NULL
that	NULL
a	NULL
significant	NULL
fraction	NULL
of	NULL
these	NULL
are	NULL
likely	NULL
to	NULL
be	NULL
the	NULL
result	NULL
of	NULL
aberrant	NULL
splicing	NULL
.	NULL

While	NULL
we	NULL
can	NULL
not	NULL
exclude	NULL
that	NULL
alterations	NULL
in	NULL
TSGI01	NULL
and	NULL
FHIT	NULL
occur	NULL
during	NULL
cancer	NULL
development	NULL
,	NULL
our	NULL
data	NULL
indicate	NULL
that	NULL
in	NULL
this	NULL
context	NULL
the	NULL
commonly	NULL
observed	NULL
transcript	NULL
abnormalities	NULL
are	NULL
misleading	NULL
.	NULL

Keywords	NULL
:	NULL
TSGI01	NULL
;	NULL
FHIT	NULL
;	NULL
splicing	NULL
;	NULL
tumour	NULL
Introduction	NULL
tsg1I01	NULL
is	NULL
a	NULL
gene	NULL
whose	NULL
functional	NULL
inactivation	NULL
transforms	NULL
mouse	NULL
fibroblasts	NULL
to	NULL
cells	NULL
that	NULL
form	NULL
metastatic	NULL
tumours	NULL
in	NULL
nude	NULL
mice	NULL
(	NULL
Li	NULL
and	NULL
Cohen	NULL
,	NULL
1996	NULL
)	NULL
.	NULL

Reversal	NULL
of	NULL
tsg10l	NULL
inactivation	NULL
reverses	NULL
the	NULL
transformed	NULL
Correspondence	NULL
:	NULL
C	NULL
Caldas	NULL
*These	NULL
authors	NULL
contributed	NULL
equally	NULL
to	NULL
the	NULL
study	NULL
Received	NULL
8	NULL
August	NULL
1997	NULL
;	NULL
revised	NULL
23	NULL
September	NULL
1997	NULL
;	NULL
accepted	NULL
24	NULL
September	NULL
1997	NULL
phenotype	NULL
and	NULL
suppresses	NULL
malignant	NULL
growth	NULL
(	NULL
Li	NULL
and	NULL
Cohen	NULL
,	NULL
1996	NULL
)	NULL
.	NULL

The	NULL
human	NULL
homologue	NULL
(	NULL
TSGI01	NULL
!	NULL
)	NULL

is	NULL
86	NULL
%	NULL
identical	NULL
to	NULL
mouse	NULL
tsg101	NULL
and	NULL
consists	NULL
of	NULL
an	NULL
open	NULL
reading	NULL
frame	NULL
(	NULL
ORF	NULL
)	NULL
of	NULL
1140	NULL
bp	NULL
which	NULL
is	NULL
predicted	NULL
to	NULL
encode	NULL
a	NULL
protein	NULL
of	NULL
380	NULL
amino	NULL
acids	NULL
(	NULL
Li	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
.	NULL

TSGIO1	NULL
is	NULL
localized	NULL
to	NULL
chromosome	NULL
11p15.1-15.2	NULL
,	NULL
a	NULL
region	NULL
at	NULL
which	NULL
loss	NULL
of	NULL
heterozygosity	NULL
(	NULL
LOH	NULL
)	NULL
is	NULL
frequently	NULL
observed	NULL
in	NULL
breast	NULL
,	NULL
ovarian	NULL
and	NULL
testicular	NULL
cancers	NULL
and	NULL
in	NULL
Wilms	NULL
'	NULL
tumour	NULL
,	NULL
suggesting	NULL
that	NULL
one	NULL
or	NULL
more	NULL
tumour	NULL
suppressor	NULL
genes	NULL
reside	NULL
in	NULL
this	NULL
region	NULL
(	NULL
Li	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
.	NULL

Analysis	NULL
of	NULL
RNA	NULL
derived	NULL
from	NULL
breast	NULL
tumour	NULL
tissue	NULL
identified	NULL
large	NULL
deletions	NULL
and	NULL
insertions	NULL
within	NULL
the	NULL
coding	NULL
region	NULL
of	NULL
TSGI01	NULL
in	NULL
seven	NULL
of	NULL
15	NULL
tumours	NULL
;	NULL
these	NULL
alterations	NULL
were	NULL
absent	NULL
in	NULL
RNA	NULL
from	NULL
matching	NULL
normal	NULL
breast	NULL
tissue	NULL
(	NULL
Li	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
.	NULL

All	NULL
of	NULL
these	NULL
deletions	NULL
removed	NULL
part	NULL
or	NULL
all	NULL
of	NULL
the	NULL
coiled-coil	NULL
domain	NULL
and	NULL
were	NULL
predicted	NULL
to	NULL
truncate	NULL
the	NULL
TSGI01	NULL
!	NULL

protein	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
6	NULL
tumours	NULL
which	NULL
contained	NULL
deletions	NULL
in	NULL
TSGIO	NULL
!	NULL

transcripts	NULL
appeared	NULL
also	NULL
to	NULL
contain	NULL
deletions	NULL
in	NULL
genomic	NULL
DNA	NULL
which	NULL
had	NULL
been	NULL
analysed	NULL
using	NULL
a	NULL
PCR	NULL
amplification	NULL
based	NULL
Southern	NULL
blot	NULL
hybridization	NULL
(	NULL
Li	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
.	NULL

The	NULL
alterations	NULL
reported	NULL
in	NULL
TSGIO	NULL
!	NULL

in	NULL
primary	NULL
breast	NULL
tumours	NULL
are	NULL
similar	NULL
in	NULL
type	NULL
to	NULL
alterations	NULL
reported	NULL
in	NULL
another	NULL
candidate	NULL
tumour	NULL
suppressor	NULL
gene	NULL
,	NULL
FHIT	NULL
(	NULL
Ohta	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
;	NULL
Sozz	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
.	NULL

The	NULL
FHIT	NULL
(	NULL
fragile	NULL
histidine	NULL
triad	NULL
)	NULL
gene	NULL
is	NULL
located	NULL
at	NULL
the	NULL
fragile	NULL
site	NULL
locus	NULL
FRA3B	NULL
on	NULL
chromosome	NULL
3p14.2	NULL
,	NULL
a	NULL
region	NULL
of	NULL
the	NULL
genome	NULL
which	NULL
shows	NULL
LOH	NULL
in	NULL
a	NULL
variety	NULL
of	NULL
cancers	NULL
including	NULL
small	NULL
cell	NULL
lung	NULL
cancers	NULL
(	NULL
SCLC	NULL
)	NULL
and	NULL
non-small	NULL
cell	NULL
lung	NULL
cancers	NULL
(	NULL
NSCLC	NULL
)	NULL
(	NULL
Sozzi	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
.	NULL

FHIT	NULL
contains	NULL
an	NULL
ORF	NULL
of	NULL
444	NULL
bp	NULL
encoding	NULL
a	NULL
protein	NULL
of	NULL
147	NULL
amino	NULL
acids	NULL
,	NULL
which	NULL
appears	NULL
to	NULL
be	NULL
ubiquitously	NULL
expressed	NULL
in	NULL
human	NULL
tissues	NULL
at	NULL
low	NULL
levels	NULL
.	NULL

Large	NULL
deletions	NULL
within	NULL
FHIT	NULL
transcripts	NULL
occur	NULL
frequently	NULL
in	NULL
SCLC	NULL
,	NULL
NSCLC	NULL
and	NULL
carcinomas	NULL
of	NULL
the	NULL
oesophagus	NULL
,	NULL
stomach	NULL
,	NULL
colon	NULL
,	NULL
and	NULL
breast	NULL
(	NULL
Hayashi	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
;	NULL
Huebner	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
.	NULL

Most	NULL
of	NULL
the	NULL
deletions	NULL
described	NULL
to	NULL
date	NULL
in	NULL
FHIT	NULL
involve	NULL
loss	NULL
of	NULL
one	NULL
or	NULL
more	NULL
coding	NULL
exons	NULL
and	NULL
are	NULL
predicted	NULL
to	NULL
lead	NULL
to	NULL
truncation	NULL
of	NULL
the	NULL
FHIT	NULL
protein	NULL
(	NULL
Huebner	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
.	NULL

In	NULL
the	NULL
current	NULL
study	NULL
,	NULL
we	NULL
analysed	NULL
cDNA	NULL
from	NULL
normal	NULL
lymphocytes	NULL
and	NULL
lung	NULL
parenchyma	NULL
,	NULL
EBV-immortalised	NULL
B-cells	NULL
,	NULL
and	NULL
from	NULL
primary	NULL
ovarian	NULL
,	NULL
breast	NULL
and	NULL
lung	NULL
cancers	NULL
,	NULL
chronic	NULL
lymphocytic	NULL
leukemias	NULL
(	NULL
CLL	NULL
)	NULL
and	NULL
ovarian	NULL
,	NULL
breast	NULL
,	NULL
lung	NULL
and	NULL
melanoma	NULL
cell	NULL
lines	NULL
for	NULL
mutations	NULL
in	NULL
TSGIO0	NULL
!	NULL

and	NULL
FHIT	NULL
transcripts	NULL
.	NULL

We	NULL
also	NULL
analysed	NULL
primary	NULL
ovarian	NULL
carcino-mas	NULL
,	NULL
CLL	NULL
,	NULL
and	NULL
ovarian	NULL
and	NULL
lung	NULL
cancer	NULL
cell	NULL
lines	NULL
for	NULL
mutations	NULL
of	NULL
TSGI01	NULL
in	NULL
genomic	NULL
DNA	NULL
.	NULL

Aberrant	NULL
splicing	NULL
of	NULL
TSG101	NULL
and	NULL
FHIT	NULL
SA	NULL
Gayther	NULL
et	NULL
al	NULL
2120	NULL
Results	NULL
TSG101	NULL
transcript	NULL
analysis	NULL
in	NULL
multiple	NULL
malignancies	NULL
and	NULL
normal	NULL
tissues	NULL
cDNA	NULL
reverse	NULL
transcribed	NULL
from	NULL
RNA	NULL
prepared	NULL
from	NULL
primary	NULL
tumours	NULL
,	NULL
cancer	NULL
cell	NULL
lines	NULL
,	NULL
and	NULL
'normal	NULL
'	NULL
tissues	NULL
(	NULL
lung	NULL
parenchyma	NULL
and	NULL
EBV-immortalised	NULL
B-cells	NULL
)	NULL
,	NULL
was	NULL
used	NULL
to	NULL
PCR	NULL
amplify	NULL
the	NULL
entire	NULL
coding	NULL
region	NULL
of	NULL
TSGIO1	NULL
in	NULL
one	NULL
fragment	NULL
to	NULL
screen	NULL
for	NULL
deletions	NULL
.	NULL

The	NULL
results	NULL
of	NULL
this	NULL
analysis	NULL
are	NULL
summarised	NULL
in	NULL
Tables	NULL
1-3	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
the	NULL
normal	NULL
sized	NULL
transcript	NULL
which	NULL
was	NULL
observed	NULL
in	NULL
the	NULL
large	NULL
majority	NULL
of	NULL
samples	NULL
tested	NULL
,	NULL
one	NULL
or	NULL
more	NULL
smaller	NULL
fragments	NULL
were	NULL
frequently	NULL
seen	NULL
in	NULL
primary	NULL
ovarian	NULL
,	NULL
breast	NULL
and	NULL
lung	NULL
cancers	NULL
,	NULL
in	NULL
chronic	NULL
lymphocytic	NULL
leukemias	NULL
(	NULL
CLL	NULL
)	NULL
,	NULL
and	NULL
in	NULL
breast	NULL
cancer	NULL
,	NULL
ovarian	NULL
cancer	NULL
and	NULL
melanoma	NULL
cell	NULL
lines	NULL
(	NULL
Table	NULL
1	NULL
and	NULL
Figure	NULL
la	NULL
)	NULL
.	NULL

Although	NULL
we	NULL
used	NULL
a	NULL
nested	NULL
PCR	NULL
approach	NULL
more	NULL
than	NULL
half	NULL
of	NULL
the	NULL
deletions	NULL
were	NULL
identified	NULL
after	NULL
first	NULL
round	NULL
amplification	NULL
.	NULL

The	NULL
majority	NULL
of	NULL
TSGI01	NULL
deletions	NULL
were	NULL
reproducible	NULL
in	NULL
repeat	NULL
PCR	NULL
amplifica-tions	NULL
.	NULL

In	NULL
some	NULL
tumours	NULL
shorter	NULL
transcripts	NULL
were	NULL
predominant	NULL
,	NULL
and	NULL
full	NULL
length	NULL
TSGIO0	NULL
!	NULL

was	NULL
either	NULL
not	NULL
detectable	NULL
or	NULL
present	NULL
at	NULL
low	NULL
levels	NULL
(	NULL
Table	NULL
1	NULL
and	NULL
Figure	NULL
Table	NULL
1	NULL
-	NULL
Frequency	NULL
of	NULL
intragenic	NULL
deletions	NULL
in	NULL
TSGIO	NULL
!	NULL

transcripts	NULL
in	NULL
primary	NULL
tumours	NULL
and	NULL
cancer	NULL
cell	NULL
lines	NULL
TSG101	NULL
full	NULL
Sample	NULL
length	NULL
TSG101	NULL
deletion	NULL
Ovarian	NULL
cancer	NULL
(	NULL
primary	NULL
tumours	NULL
)	NULL
45/52	NULL
21/52	NULL
Ovarian	NULL
cancer	NULL
(	NULL
cell	NULL
lines	NULL
)	NULL
8/9	NULL
7/9	NULL
Breast	NULL
cancer	NULL
(	NULL
primary	NULL
tumours	NULL
)	NULL
8/10	NULL
6/10	NULL
Breast	NULL
cancer	NULL
(	NULL
cell	NULL
lines	NULL
)	NULL
5/16	NULL
11/16	NULL
Lung	NULL
cancer	NULL
(	NULL
primary	NULL
tumours	NULL
)	NULL
4/8	NULL
2/8	NULL
Lung	NULL
cancer	NULL
(	NULL
cell	NULL
lines	NULL
)	NULL
14/16	NULL
16/16	NULL
Melanoma	NULL
(	NULL
low	NULL
passage	NULL
cell	NULL
lines	NULL
)	NULL
2/6	NULL
6/6	NULL
Chronic	NULL
lymphocytic	NULL
leukaemia	NULL
4/8	NULL
8/8	NULL
la	NULL
)	NULL
.	NULL

Sequence	NULL
analysis	NULL
indicated	NULL
that	NULL
these	NULL
smaller	NULL
fragments	NULL
represented	NULL
TSGIO1	NULL
transcripts	NULL
containing	NULL
deletions	NULL
of	NULL
between	NULL
315	NULL
and	NULL
922	NULL
bp	NULL
(	NULL
Figure	NULL
1	NULL
;	NULL
Table	NULL
2	NULL
)	NULL
.	NULL

The	NULL
5	NULL
and/or	NULL
3	NULL
'	NULL
breakpoints	NULL
of	NULL
TSGI01	NULL
deletions	NULL
of	NULL
506	NULL
,	NULL
598	NULL
,	NULL
609	NULL
,	NULL
815	NULL
,	NULL
901	NULL
and	NULL
922	NULL
bp	NULL
were	NULL
at	NULL
genuine	NULL
splice	NULL
sites	NULL
or	NULL
at	NULL
cryptic	NULL
splice	NULL
sites	NULL
located	NULL
within	NULL
exons	NULL
(	NULL
see	NULL
Table	NULL
2	NULL
)	NULL
.	NULL

Most	NULL
of	NULL
these	NULL
deletions	NULL
are	NULL
predicted	NULL
to	NULL
truncate	NULL
the	NULL
TSGIO01	NULL
protein	NULL
and	NULL
this	NULL
was	NULL
confirmed	NULL
using	NULL
the	NULL
protein	NULL
truncation	NULL
test	NULL
(	NULL
PTT	NULL
)	NULL
.	NULL

We	NULL
also	NULL
detected	NULL
three	NULL
in-frame	NULL
deletions	NULL
of	NULL
315	NULL
,	NULL
609	NULL
and	NULL
780	NULL
bp	NULL
.	NULL

PTT	NULL
was	NULL
also	NULL
used	NULL
to	NULL
screen	NULL
for	NULL
mutations	NULL
in	NULL
TSGIO1	NULL
transcripts	NULL
which	NULL
did	NULL
not	NULL
contain	NULL
large	NULL
intragenic	NULL
deletions	NULL
.	NULL

Alterations	NULL
such	NULL
as	NULL
micro-dele-tions	NULL
and	NULL
insertions	NULL
and	NULL
nonsense	NULL
mutations	NULL
which	NULL
would	NULL
be	NULL
predicted	NULL
to	NULL
have	NULL
the	NULL
same	NULL
effect	NULL
as	NULL
the	NULL
larger	NULL
deletions	NULL
(	NULL
i.e	NULL
.	NULL

to	NULL
lead	NULL
to	NULL
truncation	NULL
of	NULL
the	NULL
protein	NULL
)	NULL
were	NULL
not	NULL
detected	NULL
in	NULL
any	NULL
of	NULL
the	NULL
samples	NULL
tested	NULL
.	NULL

Finally	NULL
,	NULL
a	NULL
combination	NULL
of	NULL
single	NULL
strand	NULL
conformation	NULL
analysis	NULL
and	NULL
heteroduplex	NULL
analysis	NULL
(	NULL
SSCA/HA	NULL
)	NULL
was	NULL
used	NULL
to	NULL
screen	NULL
the	NULL
coding	NULL
region	NULL
of	NULL
the	NULL
gene	NULL
for	NULL
more	NULL
subtle	NULL
mutations	NULL
;	NULL
once	NULL
again	NULL
no	NULL
alterations	NULL
were	NULL
identified	NULL
.	NULL

We	NULL
also	NULL
analysed	NULL
TSGI01	NULL
for	NULL
transcript	NULL
deletions	NULL
in	NULL
normal	NULL
tissues	NULL
.	NULL

Intragenic	NULL
deletions	NULL
were	NULL
frequently	NULL
observed	NULL
in	NULL
normal	NULL
lung	NULL
parenchyma	NULL
and	NULL
EBV	NULL
transformed	NULL
lymphocytes	NULL
(	NULL
Table	NULL
3	NULL
)	NULL
.	NULL

In	NULL
all	NULL
of	NULL
these	NULL
samples	NULL
the	NULL
full-length	NULL
TSGIO1	NULL
!	NULL

transcript	NULL
was	NULL
also	NULL
present	NULL
.	NULL

The	NULL
spectrum	NULL
of	NULL
deletions	NULL
appears	NULL
to	NULL
differ	NULL
between	NULL
tumour	NULL
and	NULL
normal	NULL
samples	NULL
;	NULL
the	NULL
315	NULL
bp	NULL
in-frame	NULL
deletion	NULL
was	NULL
the	NULL
most	NULL
frequently	NULL
observed	NULL
alteration	NULL
in	NULL
normal	NULL
tissues	NULL
and	NULL
the	NULL
in-frame	NULL
deletion	NULL
of	NULL
780	NULL
bp	NULL
was	NULL
only	NULL
seen	NULL
in	NULL
a	NULL
normal	NULL
sample	NULL
(	NULL
Table	NULL
2	NULL
)	NULL
.	NULL

However	NULL
,	NULL
we	NULL
also	NULL
detected	NULL
the	NULL
922	NULL
,	NULL
901	NULL
and	NULL
598	NULL
bp	NULL
deletions	NULL
,	NULL
which	NULL
were	NULL
more	NULL
frequently	NULL
seen	NULL
in	NULL
tumours	NULL
,	NULL
in	NULL
normal	NULL
samples	NULL
.	NULL

The	NULL
spectrum	NULL
of	NULL
deletions	NULL
observed	NULL
in	NULL
both	NULL
tumour	NULL
and	NULL
normal	NULL
tissues	NULL
is	NULL
illustrated	NULL
in	NULL
Figure	NULL
1b	NULL
and	NULL
summarised	NULL
in	NULL
Table	NULL
2	NULL
.	NULL

Table	NULL
2	NULL
Molecular	NULL
characterization	NULL
of	NULL
intragenic	NULL
deletions	NULL
in	NULL
TSGI01	NULL
transcripts	NULL
in	NULL
all	NULL
samples	NULL
Deletion	NULL
Sequence	NULL
flanking	NULL
size	NULL
cDNA	NULL
sequence	NULL
breakpoints	NULL
Tumours	NULL
Normals®	NULL
922	NULL
bp	NULL
del	NULL
133-1054	NULL
CAAG	NULL
]	NULL
taq	NULL
...	NULL
..	NULL
cagcTCcC	NULL
8/125	NULL
(	NULL
6	NULL
%	NULL
)	NULL
1/44	NULL
(	NULL
2	NULL
%	NULL
)	NULL
901	NULL
bp	NULL
del	NULL
154-1054	NULL
AACTgta	NULL
...	NULL
...	NULL
cagcTeCcC	NULL
64/125	NULL
(	NULL
51	NULL
%	NULL
)	NULL
7/44	NULL
(	NULL
16	NULL
%	NULL
)	NULL
815	NULL
bp	NULL
del	NULL
141-955	NULL
AATACaga	NULL
...	NULL
tagAACTT	NULL
5/125	NULL
(	NULL
4	NULL
%	NULL
)	NULL
780	NULL
bp	NULL
del	NULL
398-1178	NULL
ATGTiga	NULL
...	NULL
...	NULL
tgtACGT	NULL
-	NULL
1/44	NULL
(	NULL
2	NULL
%	NULL
)	NULL
609	NULL
bp	NULL
del	NULL
361-969	NULL
TAAGect	NULL
...	NULL
...	NULL
aagAAGGAT	NULL
3/125	NULL
(	NULL
2	NULL
%	NULL
)	NULL
598	NULL
bp	NULL
del	NULL
133-730	NULL
CAAGItac	NULL
...	NULL
..	NULL
cag	NULL
8/125	NULL
(	NULL
6	NULL
%	NULL
)	NULL
1/44	NULL
(	NULL
2	NULL
%	NULL
)	NULL
568	NULL
bp	NULL
del	NULL
546-1113	NULL
CGCCata	NULL
...	NULL
...	NULL
actATCTT	NULL
9/125	NULL
(	NULL
7	NULL
%	NULL
)	NULL
538	NULL
bp	NULL
del	NULL
330-867	NULL
ACATAcec	NULL
...	NULL
.	NULL

acaGAAGA	NULL
1/125	NULL
(	NULL
0.8	NULL
%	NULL
)	NULL
506	NULL
bp	NULL
del	NULL
133-639	NULL
CAAGItaqc	NULL
...	NULL
..	NULL
cag	NULL
TGGTT	NULL
1/125	NULL
(	NULL
0.8	NULL
%	NULL
)	NULL
12/44	NULL
(	NULL
27	NULL
%	NULL
)	NULL
315	NULL
bp	NULL
del	NULL
133-447	NULL
CAAGItaqc	NULL
...	NULL
..	NULL
cacCCACA	NULL
6/125	NULL
(	NULL
5	NULL
%	NULL
)	NULL
22/44	NULL
(	NULL
50	NULL
%	NULL
)	NULL
``	NULL
Nucleotides	NULL
included	NULL
in	NULL
the	NULL
fusion	NULL
truncated	NULL
transcript	NULL
are	NULL
in	NULL
uppercase	NULL
lettering	NULL
,	NULL
flanking	NULL
sequences	NULL
in	NULL
lowercase	NULL
lettering	NULL
.	NULL

Italicised	NULL
characters	NULL
are	NULL
potential	NULL
splice	NULL
donor	NULL
(	NULL
'	NULL
g	NULL
?	NULL
'	NULL

)	NULL
and	NULL
acceptor	NULL
(	NULL
'ag	NULL
``	NULL
)	NULL
sites	NULL
.	NULL
'	NULL

[	NULL
'	NULL
represents	NULL
the	NULL
beginning	NULL
of	NULL
an	NULL
exon	NULL
,	NULL
where	NULL
the	NULL
junction	NULL
lies	NULL
.	NULL

The	NULL
deletions	NULL
of	NULL
901	NULL
bp	NULL
and	NULL
922	NULL
bp	NULL
share	NULL
the	NULL
same	NULL
distal	NULL
breakpoint	NULL
(	NULL
cagCTCCC	NULL
)	NULL
;	NULL
the	NULL
315	NULL
bp	NULL
,	NULL
506	NULL
bp	NULL
,	NULL
598	NULL
bp	NULL
and	NULL
922	NULL
bp	NULL
deletions	NULL
share	NULL
the	NULL
same	NULL
proximal	NULL
breakpoint	NULL
(	NULL
CAACi	NULL
]	NULL
tac	NULL
)	NULL
.	NULL

*Normal	NULL
samples	NULL
include	NULL
12	NULL
peripheral	NULL
bloods	NULL
,	NULL
22	NULL
EBV-immortalised	NULL
B-cell	NULL
lines	NULL
and	NULL
10	NULL
lung	NULL
parenchyma	NULL
samples	NULL
Table	NULL
3	NULL
Intragenic	NULL
deletions	NULL
of	NULL
TSGI01	NULL
!	NULL

and	NULL
FHIT	NULL
transcripts	NULL
in	NULL
normal	NULL
tissues	NULL
TSGI01	NULL
FHIT	NULL
Tissue	NULL
type	NULL
Deletions	NULL
Full-length	NULL
Deletions	NULL
Full-length	NULL
Lung	NULL
parenchyma	NULL
5/10	NULL
(	NULL
50	NULL
%	NULL
)	NULL
10/10	NULL
5/6	NULL
(	NULL
83	NULL
%	NULL
)	NULL
5/6	NULL
EBV-transformed	NULL
B-lymphocytes	NULL
16/22	NULL
(	NULL
73	NULL
%	NULL
)	NULL
22/22	NULL
5/22	NULL
(	NULL
23	NULL
%	NULL
)	NULL
21/22	NULL
Peripheral	NULL
blood	NULL
7/12	NULL
(	NULL
58	NULL
%	NULL
)	NULL
12/12	NULL
3/12	NULL
(	NULL
25	NULL
%	NULL
)	NULL
11/12	NULL
(	NULL
fresh	NULL
preparation	NULL
)	NULL
Peripheral	NULL
blood	NULL
12/12	NULL
(	NULL
100	NULL
%	NULL
)	NULL
7/12	NULL
7/12	NULL
(	NULL
58	NULL
%	NULL
)	NULL
7/12	NULL
(	NULL
60h	NULL
preparation	NULL
)	NULL
TSG101	NULL
genomic	NULL
DNA	NULL
analysis	NULL
We	NULL
performed	NULL
three	NULL
types	NULL
of	NULL
analysis	NULL
to	NULL
search	NULL
for	NULL
deletions	NULL
in	NULL
genomic	NULL
DNA	NULL
that	NULL
might	NULL
correspond	NULL
to	NULL
deleted	NULL
transcripts	NULL
in	NULL
the	NULL
same	NULL
tissues	NULL
:	NULL
PCR	NULL
amplification	NULL
with	NULL
primers	NULL
flanking	NULL
the	NULL
breakpoints	NULL
of	NULL
deletions	NULL
identified	NULL
in	NULL
the	NULL
aberrant	NULL
transcripts	NULL
,	NULL
PCR-Southern	NULL
blot	NULL
analysis	NULL
and	NULL
Southern	NULL
blot	NULL
hybridization	NULL
of	NULL
restriction	NULL
enzyme	NULL
digested	NULL
genomic	NULL
DNA	NULL
.	NULL

(	NULL
1	NULL
)	NULL
PCR	NULL
primers	NULL
located	NULL
in	NULL
exons	NULL
1	NULL
and	NULL
5	NULL
,	NULL
and	NULL
flanking	NULL
breakpoints	NULL
of	NULL
three	NULL
TSGI01	NULL
transcript	NULL
deletions	NULL
(	NULL
568	NULL
,	NULL
598	NULL
and	NULL
901	NULL
bp	NULL
)	NULL
,	NULL
were	NULL
used	NULL
in	NULL
an	NULL
attempt	NULL
to	NULL
amplify	NULL
the	NULL
predicted	NULL
genomic	NULL
DNA	NULL
product	NULL
that	NULL
would	NULL
correspond	NULL
to	NULL
transcript	NULL
deletions	NULL
in	NULL
ovarian	NULL
cancer	NULL
and	NULL
CLL	NULL
samples	NULL
.	NULL

We	NULL
were	NULL
unable	NULL
to	NULL
amplify	NULL
any	NULL
genomic	NULL
DNA	NULL
product	NULL
,	NULL
whereas	NULL
in	NULL
a	NULL
simultaneous	NULL
control	NULL
the	NULL
deleted	NULL
transcript	NULL
was	NULL
amplified	NULL
from	NULL
the	NULL
corresponding	NULL
cDNA	NULL
sample	NULL
using	NULL
the	NULL
same	NULL
primers	NULL
and	NULL
PCR	NULL
conditions	NULL
.	NULL

(	NULL
2	NULL
)	NULL
Genomic	NULL
DNA	NULL
,	NULL
from	NULL
47	NULL
ovarian	NULL
tumours	NULL
and	NULL
matching	NULL
bloods	NULL
,	NULL
five	NULL
breast	NULL
and	NULL
ovarian	NULL
cancer	NULL
cell	NULL
lines	NULL
and	NULL
four	NULL
CLL	NULL
samples	NULL
,	NULL
were	NULL
amplified	NULL
using	NULL
nested	NULL
PCR	NULL
with	NULL
Aberrant	NULL
splicing	NULL
of	NULL
TSG101	NULL
and	NULL
FHIT	NULL
SA	NULL
Gayther	NULL
et	NULL
al	NULL
primers	NULL
that	NULL
flank	NULL
the	NULL
breakpoints	NULL
of	NULL
all	NULL
of	NULL
the	NULL
deletions	NULL
we	NULL
identified	NULL
in	NULL
RNA	NULL
transcripts	NULL
.	NULL

Products	NULL
of	NULL
amplification	NULL
were	NULL
Southern	NULL
blotted	NULL
and	NULL
hybridized	NULL
with	NULL
a	NULL
full-length	NULL
TSGI01	NULL
cDNA	NULL
probe	NULL
.	NULL

Multiple	NULL
PCR	NULL
fragments	NULL
hybridized	NULL
.	NULL

Six	NULL
different	NULL
fragments	NULL
which	NULL
hybridized	NULL
were	NULL
cloned	NULL
and	NULL
sequenced	NULL
;	NULL
five	NULL
were	NULL
shown	NULL
to	NULL
be	NULL
amplification	NULL
artefacts	NULL
.	NULL

The	NULL
sixth	NULL
fragment	NULL
,	NULL
amplified	NULL
from	NULL
a	NULL
normal	NULL
sample	NULL
,	NULL
represented	NULL
TSGIO1	NULL
related	NULL
sequence	NULL
:	NULL
the	NULL
sense	NULL
primer	NULL
is	NULL
followed	NULL
by	NULL
an	NULL
additional	NULL
11	NULL
bp	NULL
of	NULL
TSG101	NULL
coding	NULL
sequence	NULL
before	NULL
it	NULL
diverges	NULL
at	NULL
nucleotide	NULL
132	NULL
,	NULL
the	NULL
precise	NULL
location	NULL
of	NULL
the	NULL
5	NULL
breakpoint	NULL
of	NULL
deletions	NULL
of	NULL
315	NULL
,	NULL
506	NULL
,	NULL
598	NULL
and	NULL
922	NULL
bp	NULL
.	NULL

The	NULL
sequence	NULL
at	NULL
the	NULL
point	NULL
of	NULL
divergence	NULL
represents	NULL
a	NULL
potential	NULL
consensus	NULL
splice	NULL
donor	NULL
site	NULL
(	NULL
CAAGgt	NULL
)	NULL
,	NULL
but	NULL
we	NULL
have	NULL
not	NULL
obtained	NULL
further	NULL
evidence	NULL
that	NULL
an	NULL
intron	NULL
divides	NULL
exon	NULL
1	NULL
at	NULL
nucleotide	NULL
132	NULL
.	NULL

(	NULL
3	NULL
)	NULL
Southern	NULL
blot	NULL
hybridization	NULL
analysis	NULL
was	NULL
performed	NULL
using	NULL
genomic	NULL
DNA	NULL
from	NULL
19	NULL
ovarian	NULL
tumours	NULL
digested	NULL
with	NULL
EcoRI	NULL
and	NULL
from	NULL
six	NULL
ovarian	NULL
and	NULL
lung	NULL
cancer	NULL
cell	NULL
lines	NULL
digested	NULL
with	NULL
EcoRI	NULL
,	NULL
BamHI	NULL
and	NULL
HindIII	NULL
;	NULL
most	NULL
of	NULL
these	NULL
samples	NULL
had	NULL
intragenic	NULL
TSGI01	NULL
transcript	NULL
deletions	NULL
.	NULL

By	NULL
using	NULL
DNA	NULL
a	NULL
full	NULL
length	NULL
transcript	NULL
deletion	NULL
transcripts	NULL
b	NULL
ATG	NULL
TAG	NULL
|	NULL
1	NULL
|a	NULL
]	NULL
s	NULL
|	NULL
4	NULL
_|	NULL
s	NULL
|	NULL
6	NULL
|	NULL
A133	NULL
to	NULL
1054	NULL
(	NULL
922	NULL
bp	NULL
)	NULL
-	NULL
RRR	NULL
-	NULL
-	NULL
-	NULL
-	NULL
--	NULL
-=	NULL
--	NULL
<	NULL
-	NULL
«	NULL
-o-	NULL
--	NULL
-	NULL
-	NULL
-o	NULL
-	NULL
--	NULL
e	NULL
A	NULL
154	NULL
to	NULL
1054	NULL
(	NULL
901	NULL
bp	NULL
)	NULL
_	NULL
RRR	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-o-	NULL
--	NULL
-	NULL
-o-	NULL
-	NULL
-	NULL
<	NULL
-	NULL
-	NULL
-	NULL
-	NULL
--	NULL
Hm	NULL
A	NULL
141	NULL
to	NULL
955	NULL
(	NULL
815	NULL
bp	NULL
)	NULL
_	NULL
ERR	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-o-	NULL
-	NULL
-	NULL
<	NULL
<	NULL
n	NULL
n	NULL
e	NULL
-	NULL
-	NULL
-	NULL
=	NULL
Em	NULL
A	NULL
398	NULL
to	NULL
1178	NULL
(	NULL
780	NULL
op	NULL
)	NULL
_-	NULL
Ee	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
--	NULL
[	NULL
A	NULL
361	NULL
to	NULL
969	NULL
(	NULL
60	NULL
%	NULL
op	NULL
)	NULL
-_	NULL
Rem	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
~	NULL
A133	NULL
to	NULL
730	NULL
(	NULL
598	NULL
bp	NULL
)	NULL
_.	NULL
RRR	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-o-	NULL
o-	NULL
--	NULL
--	NULL
-	NULL
m	NULL
A	NULL
546	NULL
to	NULL
1113	NULL
(	NULL
568	NULL
bp	NULL
)	NULL
-	NULL
Rm	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
Ee	NULL
A	NULL
330	NULL
to	NULL
867	NULL
(	NULL
538	NULL
bp	NULL
)	NULL
_	NULL
Rem	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
--	NULL
-	NULL
a	NULL
A	NULL
133	NULL
to	NULL
639	NULL
(	NULL
506	NULL
bp	NULL
)	NULL
_-	NULL
.	NULL

Rem	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
--	NULL
-	NULL
-	NULL
-~	NULL
P	NULL
A	NULL
133	NULL
to	NULL
447	NULL
(	NULL
315	NULL
bp	NULL
)	NULL
_-	NULL
RE-	NULL
-	NULL
-	NULL
-	NULL
--	NULL
-	NULL
r	NULL
Figure	NULL
1	NULL
-	NULL
(	NULL
a	NULL
)	NULL
RT-PCR	NULL
amplification	NULL
of	NULL
TSGI01	NULL
transcripts	NULL
in	NULL
13	NULL
primary	NULL
ovarian	NULL
cancers	NULL
.	NULL

Full	NULL
length	NULL
TSG101	NULL
is	NULL
the	NULL
predominant	NULL
transcript	NULL
in	NULL
samples	NULL
1-4	NULL
,	NULL
7	NULL
,	NULL
9-11	NULL
and	NULL
13	NULL
.	NULL

Full-length	NULL
TSG1O1	NULL
is	NULL
either	NULL
absent	NULL
or	NULL
at	NULL
low	NULL
levels	NULL
in	NULL
samples	NULL
5	NULL
,	NULL
6	NULL
,	NULL
8	NULL
and	NULL
12	NULL
.	NULL

Smaller	NULL
fragments	NULL
which	NULL
represent	NULL
transcripts	NULL
containing	NULL
deletions	NULL
can	NULL
be	NULL
seen	NULL
in	NULL
samples	NULL
3	NULL
,	NULL
9	NULL
and	NULL
11	NULL
(	NULL
deletion	NULL
of	NULL
315	NULL
bp	NULL
)	NULL
;	NULL
5	NULL
,	NULL
6	NULL
and	NULL
12	NULL
(	NULL
901	NULL
bp	NULL
)	NULL
;	NULL
8	NULL
and	NULL
12	NULL
(	NULL
568	NULL
bp	NULL
)	NULL
.	NULL

(	NULL
b	NULL
)	NULL
The	NULL
spectrum	NULL
of	NULL
deletions	NULL
identified	NULL
in	NULL
RNA	NULL
transcripts	NULL
from	NULL
multiple	NULL
tumours	NULL
and	NULL
normal	NULL
samples	NULL
in	NULL
the	NULL
TSGIO1	NULL
gene	NULL
.	NULL

For	NULL
each	NULL
case	NULL
,	NULL
the	NULL
dashed	NULL
line	NULL
represents	NULL
the	NULL
deleted	NULL
portion	NULL
of	NULL
the	NULL
transcript	NULL
.	NULL

Exons	NULL
within	NULL
the	NULL
gene	NULL
schematic	NULL
are	NULL
drawn	NULL
to	NULL
scale	NULL
2121	NULL
Aberrant	NULL
splicing	NULL
of	NULL
TSG101	NULL
and	NULL
FHIT	NULL
SA	NULL
Gayther	NULL
et	NULL
al	NULL
2122	NULL
prepared	NULL
from	NULL
established	NULL
cancer	NULL
cell	NULL
lines	NULL
(	NULL
which	NULL
are	NULL
clonal	NULL
presumably	NULL
)	NULL
we	NULL
avoided	NULL
the	NULL
possible	NULL
problem	NULL
of	NULL
contaminating	NULL
normal	NULL
tissue	NULL
masking	NULL
the	NULL
presence	NULL
of	NULL
tumour	NULL
specific	NULL
DNA	NULL
fragments	NULL
of	NULL
different	NULL
sizes	NULL
.	NULL

No	NULL
evidence	NULL
of	NULL
genomic	NULL
deletion	NULL
or	NULL
rearrangement	NULL
was	NULL
seen	NULL
in	NULL
any	NULL
samples	NULL
.	NULL

In	NULL
a	NULL
recent	NULL
report	NULL
,	NULL
13	NULL
breast	NULL
cancer	NULL
cell	NULL
lines	NULL
analysed	NULL
by	NULL
Southern	NULL
blot	NULL
showed	NULL
no	NULL
evidence	NULL
of	NULL
TSG101	NULL
genomic	NULL
deletion	NULL
(	NULL
Steiner	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
.	NULL

Four	NULL
of	NULL
these	NULL
lines	NULL
(	NULL
BT-20	NULL
,	NULL
T-47D	NULL
,	NULL
MCF-7	NULL
,	NULL
MDA-MB-175	NULL
)	NULL
were	NULL
analysed	NULL
in	NULL
the	NULL
current	NULL
study	NULL
and	NULL
observed	NULL
to	NULL
have	NULL
the	NULL
901	NULL
bp	NULL
transcript	NULL
deletion	NULL
.	NULL

Finally	NULL
,	NULL
to	NULL
screen	NULL
for	NULL
more	NULL
subtle	NULL
genomic	NULL
altera-tions	NULL
,	NULL
we	NULL
used	NULL
SSCA	NULL
to	NULL
analyse	NULL
the	NULL
6	NULL
coding	NULL
exons	NULL
of	NULL
TSG101	NULL
in	NULL
genomic	NULL
DNA	NULL
from	NULL
47	NULL
sporadic	NULL
ovarian	NULL
tumours	NULL
and	NULL
matching	NULL
lymphocytes	NULL
.	NULL

No	NULL
deleterious	NULL
mutations	NULL
were	NULL
identified	NULL
.	NULL

Analysis	NULL
of	NULL
TSG1IOl	NULL
transcript	NULL
deletions	NULL
in	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
To	NULL
determine	NULL
the	NULL
presence	NULL
of	NULL
TSGIO01	NULL
truncations	NULL
in	NULL
RNA	NULL
from	NULL
'normal	NULL
'	NULL
tissues	NULL
other	NULL
than	NULL
lung	NULL
parench-	NULL
TSG101	NULL
fresh	NULL
lymphocytes	NULL
'aged	NULL
'	NULL
lymphocytes	NULL
Igf2	NULL
receptor	NULL
fresh	NULL
lymphocytes	NULL
'aged	NULL
'	NULL
lymphocytes	NULL
BRCA1	NULL
fresh	NULL
lymphocytes	NULL
'aged	NULL
'	NULL
lymphocytes	NULL
yma	NULL
and	NULL
EBV-transformed	NULL
cell	NULL
lines	NULL
,	NULL
we	NULL
decided	NULL
to	NULL
analyse	NULL
RNA	NULL
prepared	NULL
directly	NULL
from	NULL
normal	NULL
peripheral	NULL
blood	NULL
.	NULL

Blood	NULL
was	NULL
taken	NULL
from	NULL
12	NULL
healthy	NULL
individuals	NULL
;	NULL
approximately	NULL
half	NULL
the	NULL
volume	NULL
of	NULL
each	NULL
sample	NULL
was	NULL
prepared	NULL
immediately	NULL
for	NULL
RNA	NULL
and	NULL
reverse	NULL
transcribed	NULL
into	NULL
cDNA	NULL
.	NULL

The	NULL
remainder	NULL
was	NULL
incubated	NULL
at	NULL
room	NULL
temperature	NULL
for	NULL
60	NULL
h	NULL
prior	NULL
to	NULL
RNA	NULL
isolation	NULL
and	NULL
reverse	NULL
transcription	NULL
(	NULL
'aged	NULL
'	NULL
sample	NULL
)	NULL
.	NULL

Both	NULL
sets	NULL
of	NULL
cDNA	NULL
samples	NULL
were	NULL
screened	NULL
simultaneously	NULL
for	NULL
deletions	NULL
in	NULL
TSGI01	NULL
!	NULL

transcripts	NULL
.	NULL

Transcripts	NULL
containing	NULL
deletions	NULL
were	NULL
detected	NULL
in	NULL
both	NULL
fresh	NULL
and	NULL
'aged	NULL
'	NULL
samples	NULL
.	NULL

However	NULL
,	NULL
whereas	NULL
in	NULL
freshly	NULL
prepared	NULL
samples	NULL
full	NULL
length	NULL
TSGIO1	NULL
!	NULL

was	NULL
the	NULL
predominant	NULL
transcript	NULL
,	NULL
'aged	NULL
'	NULL
samples	NULL
contained	NULL
very	NULL
little	NULL
full	NULL
length	NULL
TSGI01	NULL
and	NULL
a	NULL
transcript	NULL
containing	NULL
a	NULL
truncating	NULL
deletion	NULL
of	NULL
506	NULL
bp	NULL
was	NULL
predominant	NULL
(	NULL
Figure	NULL
2a	NULL
;	NULL
Tables	NULL
2	NULL
and	NULL
3	NULL
)	NULL
.	NULL

An	NULL
identical	NULL
deletion	NULL
was	NULL
also	NULL
observed	NULL
in	NULL
RNA	NULL
isolated	NULL
from	NULL
one	NULL
lung	NULL
cancer	NULL
and	NULL
from	NULL
primary	NULL
breast	NULL
cancers	NULL
in	NULL
the	NULL
series	NULL
reported	NULL
by	NULL
Lee	NULL
and	NULL
Feinberg	NULL
(	NULL
1997	NULL
)	NULL
.	NULL

The	NULL
deletion	NULL
shares	NULL
a	NULL
proximal	NULL
breakpoint	NULL
with	NULL
transcript	NULL
deletions	NULL
of	NULL
315	NULL
,	NULL
598	NULL
and	NULL
922	NULL
bp	NULL
and	NULL
the	NULL
distal	NULL
breakpoint	NULL
is	NULL
at	NULL
the	NULL
boundary	NULL
FHIT	NULL
'aged	NULL
'	NULL
lymphocytes	NULL
fresh	NULL
lymphocytes	NULL
RB	NULL
fresh	NULL
lymphocytes	NULL
'aged	NULL
'	NULL
lymphocytes	NULL
BRCAZ	NULL
fresh	NULL
lymphocytes	NULL
'aged	NULL
'	NULL
lymphocytes	NULL
Figure	NULL
2	NULL
PCR	NULL
analysis	NULL
of	NULL
TSGIO1I	NULL
,	NULL
FHIT	NULL
,	NULL
Igf2	NULL
receptor	NULL
,	NULL
RB	NULL
(	NULL
retinoblastoma	NULL
)	NULL
,	NULL
BRCAI	NULL
and	NULL
BRCA2	NULL
in	NULL
cDNA	NULL
reverse	NULL
transcribed	NULL
from	NULL
RNA	NULL
in	NULL
normal	NULL
fresh	NULL
and	NULL
'aged	NULL
'	NULL
peripheral	NULL
blood	NULL
samples	NULL
.	NULL

TSGI01	NULL
!	NULL

and	NULL
FHIT	NULL
wild-type	NULL
transcripts	NULL
are	NULL
predominant	NULL
in	NULL
fresh	NULL
samples	NULL
but	NULL
there	NULL
is	NULL
evidence	NULL
of	NULL
transcripts	NULL
with	NULL
intragenic	NULL
deletions	NULL
in	NULL
some	NULL
samples	NULL
.	NULL

In	NULL
RNA	NULL
samples	NULL
from	NULL
'aged	NULL
'	NULL
lymphocytes	NULL
full-length	NULL
TSGI01	NULL
and	NULL
FHIT	NULL
transcripts	NULL
are	NULL
less	NULL
abundant	NULL
or	NULL
completely	NULL
absent	NULL
in	NULL
the	NULL
majority	NULL
of	NULL
samples	NULL
while	NULL
the	NULL
frequency	NULL
of	NULL
transcripts	NULL
with	NULL
deletions	NULL
increases	NULL
significantly	NULL
.	NULL

BRCA1I	NULL
,	NULL
BRCA2	NULL
,	NULL
RB	NULL
,	NULL
and	NULL
Igf2	NULL
receptor	NULL
full-length	NULL
transcripts	NULL
are	NULL
amplified	NULL
consistently	NULL
in	NULL
cDNA	NULL
from	NULL
both	NULL
fresh	NULL
and	NULL
'aged	NULL
'	NULL
lymphocytes	NULL
,	NULL
with	NULL
no	NULL
evidence	NULL
of	NULL
intragenic	NULL
deletions	NULL
.	NULL

In	NULL
RB	NULL
and	NULL
BRCA	NULL
!	NULL

,	NULL
additional	NULL
faint	NULL
bands	NULL
are	NULL
occasionally	NULL
seen	NULL
;	NULL
sequencing	NULL
of	NULL
these	NULL
bands	NULL
indicates	NULL
they	NULL
are	NULL
artifactual	NULL
PCR	NULL
amplification	NULL
products	NULL
between	NULL
exons	NULL
2	NULL
and	NULL
3	NULL
.	NULL

The	NULL
specificity	NULL
of	NULL
these	NULL
breakpoints	NULL
,	NULL
as	NULL
well	NULL
as	NULL
the	NULL
results	NULL
obtained	NULL
with	NULL
RT-PCR	NULL
amplification	NULL
of	NULL
other	NULL
genes	NULL
,	NULL
suggest	NULL
that	NULL
the	NULL
506	NULL
bp	NULL
deletion	NULL
is	NULL
the	NULL
result	NULL
of	NULL
alternative	NULL
aberrant	NULL
splicing	NULL
and	NULL
not	NULL
degradation	NULL
of	NULL
the	NULL
larger	NULL
wild-type	NULL
transcript	NULL
.	NULL

Comparison	NULL
between	NULL
TSGIOL	NULL
transcripts	NULL
and	NULL
other	NULL
gene	NULL
transcripts	NULL
To	NULL
assess	NULL
whether	NULL
the	NULL
difference	NULL
between	NULL
RNA	NULL
prepared	NULL
from	NULL
fresh	NULL
and	NULL
'aged	NULL
'	NULL
lymphocytes	NULL
was	NULL
a	NULL
feature	NULL
of	NULL
all	NULL
genes	NULL
or	NULL
whether	NULL
it	NULL
was	NULL
specific	NULL
to	NULL
TSG1I01	NULL
,	NULL
we	NULL
analysed	NULL
the	NULL
same	NULL
series	NULL
of	NULL
samples	NULL
for	NULL
the	NULL
presence	NULL
of	NULL
transcripts	NULL
deletions	NULL
in	NULL
other	NULL
genes	NULL
.	NULL

Fragments	NULL
spanning	NULL
multiple	NULL
exons	NULL
were	NULL
amplified	NULL
for	NULL
the	NULL
genes	NULL
BRCAI	NULL
,	NULL
BRCA2	NULL
,	NULL
BRUSHI	NULL
,	NULL
FHIT	NULL
,	NULL
hMSH2	NULL
,	NULL
IGF2	NULL
receptor	NULL
,	NULL
PGDB	NULL
and	NULL
RB	NULL
.	NULL

There	NULL
was	NULL
no	NULL
evidence	NULL
of	NULL
truncated	NULL
transcripts	NULL
containing	NULL
deletions	NULL
similar	NULL
to	NULL
those	NULL
observed	NULL
in	NULL
TSGI01	NULL
!	NULL

in	NULL
any	NULL
gene	NULL
except	NULL
for	NULL
FHIT	NULL
(	NULL
Figure	NULL
2	NULL
)	NULL
.	NULL

FHIT	NULL
has	NULL
previously	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
frequently	NULL
altered	NULL
in	NULL
a	NULL
variety	NULL
of	NULL
different	NULL
malignancies	NULL
(	NULL
Huebner	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
.	NULL

The	NULL
mutation	NULL
spectrum	NULL
reported	NULL
for	NULL
FHIT	NULL
,	NULL
large	NULL
deletions	NULL
detected	NULL
in	NULL
RNA	NULL
with	NULL
breakpoints	NULL
in	NULL
the	NULL
coding	NULL
region	NULL
and	NULL
5	NULL
'	NULL
untranslated	NULL
region	NULL
of	NULL
the	NULL
gene	NULL
,	NULL
is	NULL
similar	NULL
to	NULL
that	NULL
reported	NULL
for	NULL
TSGIO1	NULL
!	NULL

I	NULL
.	NULL

Analysis	NULL
of	NULL
fresh	NULL
and	NULL
'aged	NULL
'	NULL
lymphocyte	NULL
cDNA	NULL
samples	NULL
from	NULL
peripheral	NULL
blood	NULL
identified	NULL
FHIT	NULL
transcripts	NULL
shorter	NULL
than	NULL
full	NULL
length	NULL
transcript	NULL
in	NULL
some	NULL
cases	NULL
.	NULL

As	NULL
with	NULL
TSGI01	NULL
,	NULL
these	NULL
shorter	NULL
Aberrant	NULL
splicing	NULL
of	NULL
TSG101	NULL
and	NULL
FHIT	NULL
SA	NULL
Gayther	NULL
et	NULL
al	NULL
FHIT	NULL
transcripts	NULL
were	NULL
more	NULL
predominant	NULL
in	NULL
'aged	NULL
'	NULL
samples	NULL
(	NULL
Figure	NULL
2b	NULL
)	NULL
.	NULL

Sequence	NULL
analysis	NULL
of	NULL
these	NULL
shorter	NULL
fragments	NULL
revealed	NULL
deletions	NULL
similar	NULL
to	NULL
those	NULL
previously	NULL
reported	NULL
in	NULL
tumours	NULL
(	NULL
Figure	NULL
3b	NULL
)	NULL
.	NULL

FHIT	NULL
deletions	NULL
occur	NULL
at	NULL
the	NULL
boundaries	NULL
of	NULL
splice	NULL
sites	NULL
and	NULL
are	NULL
predicted	NULL
to	NULL
truncate	NULL
the	NULL
protein	NULL
.	NULL

Transcripts	NULL
containing	NULL
deletions	NULL
were	NULL
not	NULL
observed	NULL
in	NULL
any	NULL
of	NULL
the	NULL
other	NULL
seven	NULL
genes	NULL
and	NULL
in	NULL
these	NULL
the	NULL
integrity	NULL
of	NULL
RNA	NULL
transcripts	NULL
did	NULL
not	NULL
appear	NULL
to	NULL
differ	NULL
between	NULL
fresh	NULL
and	NULL
'aged	NULL
'	NULL
lymphocytes	NULL
(	NULL
see	NULL
Figure	NULL
2	NULL
)	NULL
.	NULL

Our	NULL
interpretation	NULL
of	NULL
this	NULL
result	NULL
is	NULL
that	NULL
the	NULL
fidelity	NULL
of	NULL
splicing	NULL
for	NULL
the	NULL
TSGI01	NULL
and	NULL
FHIT	NULL
genes	NULL
is	NULL
affected	NULL
in	NULL
'aged	NULL
'	NULL
lymphocytes	NULL
.	NULL

The	NULL
'integrity	NULL
'	NULL
of	NULL
the	NULL
transcripts	NULL
of	NULL
the	NULL
seven	NULL
control	NULL
genes	NULL
seems	NULL
to	NULL
indicate	NULL
that	NULL
RNA	NULL
degradation	NULL
is	NULL
not	NULL
a	NULL
trivial	NULL
explanation	NULL
of	NULL
our	NULL
results	NULL
.	NULL

FHIT	NULL
transcript	NULL
analysis	NULL
in	NULL
multiple	NULL
malignancies	NULL
and	NULL
normal	NULL
tissues	NULL
We	NULL
also	NULL
analysed	NULL
FHIT	NULL
transcripts	NULL
for	NULL
mutations	NULL
in	NULL
RNA	NULL
from	NULL
multiple	NULL
malignancies	NULL
and	NULL
'normal	NULL
'	NULL
tissues	NULL
.	NULL

Transcripts	NULL
containing	NULL
deletions	NULL
were	NULL
frequently	NULL
detected	NULL
in	NULL
all	NULL
samples	NULL
analysed	NULL
(	NULL
Figure	NULL
3a	NULL
;	NULL
Tables	NULL
3	NULL
and	NULL
4	NULL
)	NULL
.	NULL

The	NULL
breakpoints	NULL
of	NULL
these	NULL
deletions	NULL
occurred	NULL
at	NULL
the	NULL
boundaries	NULL
of	NULL
introns	NULL
and	NULL
exons	NULL
suggesting	NULL
that	NULL
they	NULL
were	NULL
the	NULL
result	NULL
of	NULL
aberrant	NULL
alternative	NULL
splicing	NULL
.	NULL

The	NULL
spectrum	NULL
of	NULL
deletions	NULL
observed	NULL
is	NULL
illustrated	NULL
in	NULL
Figure	NULL
3b	NULL
.	NULL

As	NULL
with	NULL
TSGIO1	NULL
!	NULL

the	NULL
presence	NULL
and	NULL
relative	NULL
abundance	NULL
of	NULL
full-length	NULL
and	NULL
truncated	NULL
transcripts	NULL
was	NULL
variable	NULL
;	NULL
in	NULL
most	NULL
cases	NULL
both	NULL
full-length	NULL
and	NULL
deleted	NULL
a	NULL
full	NULL
length	NULL
transcript	NULL
deletion	NULL
transcripts	NULL
b	NULL
ATG	NULL
TGA	NULL
1	NULL
|2|3|4|	NULL
|	NULL
6	NULL
|7|8|	NULL
9|	NULL
10	NULL
A	NULL
-110	NULL
to	NULL
348	NULL
(	NULL
458	NULL
bp	NULL
)	NULL
-	NULL
@	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
--	NULL
=	NULL
J	NULL
A-164	NULL
to	NULL
249	NULL
(	NULL
413	NULL
bp	NULL
)	NULL
-	NULL
eer	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
--	NULL
-	NULL
~	NULL
A	NULL
-110	NULL
to	NULL
279	NULL
(	NULL
389	NULL
6p	NULL
)	NULL
.s	NULL
-	NULL
-	NULL
ooo	NULL
-	NULL
-	NULL
oom	NULL
-	NULL
-	NULL
A	NULL
-17	NULL
to	NULL
348	NULL
(	NULL
365	NULL
bp	NULL
)	NULL
A	NULL
-17	NULL
to	NULL
279	NULL
(	NULL
296	NULL
bp	NULL
)	NULL
A	NULL
-17	NULL
to	NULL
247	NULL
(	NULL
266	NULL
bp	NULL
)	NULL
Figure	NULL
3	NULL
(	NULL
a	NULL
)	NULL
RT-PCR	NULL
amplification	NULL
of	NULL
FHZT	NULL
transcripts	NULL
in	NULL
13	NULL
primary	NULL
ovarian	NULL
cancers	NULL
.	NULL

Full	NULL
length	NULL
FHIT	NULL
is	NULL
the	NULL
predominant	NULL
transcript	NULL
in	NULL
samples	NULL
1-3	NULL
,	NULL
5	NULL
,	NULL
7	NULL
,	NULL
9	NULL
,	NULL
10	NULL
and	NULL
12	NULL
;	NULL
shorter	NULL
fragments	NULL
which	NULL
represent	NULL
transcripts	NULL
containing	NULL
deletions	NULL
in	NULL
FHZT	NULL
are	NULL
seen	NULL
in	NULL
samples	NULL
4-6	NULL
,	NULL
7	NULL
,	NULL
11	NULL
and	NULL
13	NULL
.	NULL

(	NULL
b	NULL
)	NULL
The	NULL
spectrum	NULL
of	NULL
deletions	NULL
identified	NULL
in	NULL
RNA	NULL
transcripts	NULL
in	NULL
FHZT	NULL
.	NULL

For	NULL
each	NULL
case	NULL
,	NULL
the	NULL
dashed	NULL
line	NULL
represents	NULL
the	NULL
deleted	NULL
portion	NULL
of	NULL
the	NULL
transcript	NULL
.	NULL

Exons	NULL
within	NULL
the	NULL
gene	NULL
schematic	NULL
are	NULL
drawn	NULL
to	NULL
scale	NULL
2123	NULL
Aberrant	NULL
splicing	NULL
of	NULL
TSG101	NULL
and	NULL
FHIT	NULL
SA	NULL
Gayther	NULL
et	NULL
al	NULL
2124	NULL
Table	NULL
4	NULL
Frequency	NULL
of	NULL
intragenic	NULL
deletions	NULL
in	NULL
FHZT	NULL
transcripts	NULL
in	NULL
primary	NULL
tumours	NULL
and	NULL
cancer	NULL
cell	NULL
lines	NULL
FHIT	NULL
deletions	NULL
22/52	NULL
(	NULL
42	NULL
%	NULL
)	NULL
4/6	NULL
(	NULL
67	NULL
%	NULL
)	NULL
6/9	NULL
(	NULL
67	NULL
%	NULL
)	NULL
3/5	NULL
(	NULL
60	NULL
%	NULL
)	NULL
11/16	NULL
(	NULL
69	NULL
%	NULL
)	NULL
4/8	NULL
(	NULL
50	NULL
%	NULL
)	NULL
1/5	NULL
(	NULL
20	NULL
%	NULL
)	NULL
Primary	NULL
tumour	NULL
samples	NULL
{	NULL
cancer	NULL
cell	NULL
lines	NULL
Ovarian	NULL
cancer	NULL
(	NULL
primary	NULL
tumours	NULL
)	NULL
Ovarian	NULL
cancer	NULL
(	NULL
cell	NULL
lines	NULL
)	NULL
Breast	NULL
cancer	NULL
(	NULL
cell	NULL
lines	NULL
)	NULL
Lung	NULL
cancer	NULL
(	NULL
primary	NULL
tumours	NULL
)	NULL
Lung	NULL
cancer	NULL
(	NULL
cell	NULL
lines	NULL
)	NULL
Melanoma	NULL
(	NULL
low	NULL
passage	NULL
cell	NULL
lines	NULL
)	NULL
Chronic	NULL
lymphocytic	NULL
leukaemia	NULL
FHIT	NULL
transcript	NULL
(	NULL
s	NULL
)	NULL
were	NULL
detected	NULL
after	NULL
a	NULL
single	NULL
round	NULL
of	NULL
PCR	NULL
amplification	NULL
,	NULL
but	NULL
in	NULL
some	NULL
cases	NULL
deletions	NULL
were	NULL
seen	NULL
only	NULL
after	NULL
nested	NULL
PCR	NULL
.	NULL

Discussion	NULL
The	NULL
data	NULL
presented	NULL
in	NULL
this	NULL
study	NULL
show	NULL
that	NULL
TSGI0	NULL
!	NULL

and	NULL
FHIT	NULL
transcripts	NULL
containing	NULL
deletions	NULL
can	NULL
be	NULL
frequently	NULL
detected	NULL
in	NULL
a	NULL
variety	NULL
of	NULL
different	NULL
malignancies	NULL
,	NULL
but	NULL
also	NULL
at	NULL
similar	NULL
frequencies	NULL
in	NULL
RNA	NULL
from	NULL
'normal	NULL
'	NULL
tissues	NULL
.	NULL

One	NULL
particular	NULL
deletion	NULL
in	NULL
TSGI01	NULL
(	NULL
of	NULL
901	NULL
bp	NULL
)	NULL
which	NULL
was	NULL
frequently	NULL
observed	NULL
in	NULL
transcripts	NULL
in	NULL
our	NULL
series	NULL
of	NULL
samples	NULL
is	NULL
identical	NULL
to	NULL
a	NULL
deletion	NULL
which	NULL
was	NULL
seen	NULL
in	NULL
transcripts	NULL
from	NULL
four	NULL
out	NULL
of	NULL
seven	NULL
primary	NULL
breast	NULL
cancers	NULL
in	NULL
the	NULL
original	NULL
report	NULL
of	NULL
TSGI01	NULL
mutations	NULL
(	NULL
Li	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
.	NULL

Analysis	NULL
of	NULL
the	NULL
sequence	NULL
flanking	NULL
this	NULL
deletion	NULL
suggests	NULL
that	NULL
the	NULL
boundaries	NULL
of	NULL
the	NULL
breakpoints	NULL
may	NULL
represent	NULL
cryptic	NULL
consensus	NULL
splice	NULL
sites	NULL
,	NULL
a	NULL
splice	NULL
donor	NULL
in	NULL
exon	NULL
1	NULL
and	NULL
a	NULL
splice	NULL
acceptor	NULL
in	NULL
exon	NULL
5	NULL
.	NULL

As	NULL
we	NULL
were	NULL
unable	NULL
to	NULL
detect	NULL
this	NULL
deletion	NULL
in	NULL
genomic	NULL
DNA	NULL
,	NULL
it	NULL
seems	NULL
likely	NULL
that	NULL
it	NULL
represents	NULL
an	NULL
aberrant	NULL
splice	NULL
variant	NULL
in	NULL
both	NULL
malignant	NULL
and	NULL
'normal	NULL
'	NULL
tissues	NULL
.	NULL

Inspection	NULL
of	NULL
the	NULL
sequences	NULL
flanking	NULL
the	NULL
breakpoints	NULL
of	NULL
other	NULL
deletions	NULL
indicated	NULL
that	NULL
in	NULL
six	NULL
out	NULL
of	NULL
10	NULL
deleted	NULL
transcripts	NULL
a	NULL
genuine	NULL
or	NULL
a	NULL
cryptic	NULL
splice	NULL
site	NULL
is	NULL
located	NULL
adjacent	NULL
to	NULL
the	NULL
proximal	NULL
and/or	NULL
distal	NULL
breakpoints	NULL
of	NULL
the	NULL
deletion	NULL
.	NULL

TSGI01	NULL
transcripts	NULL
with	NULL
deletions	NULL
of	NULL
922	NULL
,	NULL
598	NULL
,	NULL
506	NULL
and	NULL
315	NULL
bp	NULL
share	NULL
a	NULL
common	NULL
proximal	NULL
breakpoint	NULL
at	NULL
nucleotide	NULL
132	NULL
.	NULL

The	NULL
315	NULL
bp	NULL
deletion	NULL
has	NULL
been	NULL
reported	NULL
to	NULL
be	NULL
present	NULL
in	NULL
an	NULL
EST	NULL
(	NULL
AA214591	NULL
)	NULL
from	NULL
normal	NULL
human	NULL
brain	NULL
(	NULL
BLAST	NULL
search	NULL
conducted	NULL
at	NULL
NCBI	NULL
)	NULL
,	NULL
and	NULL
is	NULL
also	NULL
seen	NULL
in	NULL
normal	NULL
breast	NULL
and	NULL
several	NULL
different	NULL
foetal	NULL
tissues	NULL
(	NULL
Lee	NULL
and	NULL
Feinberg	NULL
,	NULL
1997	NULL
)	NULL
.	NULL

Distal	NULL
breakpoints	NULL
of	NULL
deletions	NULL
of	NULL
506	NULL
,	NULL
598	NULL
,	NULL
609	NULL
,	NULL
815	NULL
,	NULL
901	NULL
and	NULL
922	NULL
bp	NULL
occur	NULL
at	NULL
genuine	NULL
or	NULL
cryptic	NULL
splice	NULL
acceptor	NULL
sequences	NULL
(	NULL
Table	NULL
2	NULL
)	NULL
.	NULL

It	NULL
appears	NULL
,	NULL
therefore	NULL
,	NULL
that	NULL
aberrant	NULL
splicing	NULL
may	NULL
be	NULL
the	NULL
underlying	NULL
mechanism	NULL
for	NULL
most	NULL
of	NULL
the	NULL
truncated	NULL
transcripts	NULL
we	NULL
detected	NULL
.	NULL

Aberrant	NULL
splicing	NULL
has	NULL
also	NULL
been	NULL
proposed	NULL
as	NULL
a	NULL
cause	NULL
of	NULL
TSGI01	NULL
deletions	NULL
(	NULL
of	NULL
315	NULL
,	NULL
506	NULL
,	NULL
598	NULL
and	NULL
901	NULL
bp	NULL
)	NULL
in	NULL
RNA	NULL
transcripts	NULL
from	NULL
breast	NULL
cancer	NULL
(	NULL
Lee	NULL
and	NULL
Feinberg	NULL
,	NULL
1997	NULL
)	NULL
.	NULL

Four	NULL
of	NULL
ten	NULL
deletions	NULL
in	NULL
transcripts	NULL
reported	NULL
in	NULL
the	NULL
original	NULL
description	NULL
of	NULL
TSG1O1	NULL
mutations	NULL
in	NULL
breast	NULL
cancer	NULL
are	NULL
similar	NULL
to	NULL
those	NULL
attributable	NULL
to	NULL
alternative	NULL
and	NULL
aberrant	NULL
splicing	NULL
.	NULL

We	NULL
also	NULL
identified	NULL
deletions	NULL
in	NULL
which	NULL
both	NULL
of	NULL
the	NULL
breakpoints	NULL
of	NULL
the	NULL
deletion	NULL
did	NULL
not	NULL
correspond	NULL
to	NULL
splice	NULL
site	NULL
sequences	NULL
(	NULL
538	NULL
and	NULL
780	NULL
bp	NULL
)	NULL
;	NULL
the	NULL
mechanism	NULL
by	NULL
which	NULL
these	NULL
deletions	NULL
might	NULL
have	NULL
occurred	NULL
is	NULL
unclear	NULL
.	NULL

Analysis	NULL
of	NULL
genomic	NULL
DNA	NULL
from	NULL
primary	NULL
ovarian	NULL
cancers	NULL
,	NULL
cancer	NULL
cell	NULL
lines	NULL
,	NULL
CLL	NULL
and	NULL
EBV-immortalised	NULL
B-cells	NULL
did	NULL
not	NULL
show	NULL
any	NULL
genomic	NULL
deletions	NULL
corre-	NULL
sponding	NULL
to	NULL
transcript	NULL
deletions	NULL
in	NULL
the	NULL
same	NULL
samples	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
we	NULL
did	NULL
not	NULL
detect	NULL
any	NULL
more	NULL
subtle	NULL
mutations	NULL
in	NULL
genomic	NULL
DNA	NULL
or	NULL
cDNA	NULL
using	NULL
SSCA/	NULL
HA	NULL
and	NULL
PTT	NULL
(	NULL
in	NULL
more	NULL
than	NULL
100	NULL
samples	NULL
analysed	NULL
)	NULL
.	NULL

Southern	NULL
blot	NULL
data	NULL
obtained	NULL
by	NULL
us	NULL
as	NULL
well	NULL
as	NULL
others	NULL
is	NULL
now	NULL
available	NULL
from	NULL
118	NULL
primary	NULL
breast	NULL
cancers	NULL
,	NULL
19	NULL
primary	NULL
ovarian	NULL
cancers	NULL
,	NULL
and	NULL
19	NULL
breast	NULL
,	NULL
ovarian	NULL
and	NULL
lung	NULL
cancer	NULL
cell	NULL
lines	NULL
,	NULL
and	NULL
to	NULL
date	NULL
no	NULL
TSG101	NULL
genomic	NULL
rearrangements	NULL
have	NULL
been	NULL
seen	NULL
.	NULL

In	NULL
the	NULL
present	NULL
study	NULL
,	NULL
truncated	NULL
FHIT	NULL
transcripts	NULL
were	NULL
frequently	NULL
detected	NULL
in	NULL
all	NULL
types	NULL
of	NULL
malignancy	NULL
and	NULL
normal	NULL
tissues	NULL
analysed	NULL
.	NULL

Deletions	NULL
in	NULL
the	NULL
coding	NULL
region	NULL
of	NULL
FHIT	NULL
transcripts	NULL
have	NULL
been	NULL
reported	NULL
in	NULL
a	NULL
variety	NULL
of	NULL
cancers	NULL
including	NULL
lung	NULL
,	NULL
gastric	NULL
,	NULL
oesophageal	NULL
and	NULL
breast	NULL
tumours	NULL
(	NULL
Hayashi	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
;	NULL
Huebner	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
.	NULL

More	NULL
recently	NULL
at	NULL
least	NULL
two	NULL
groups	NULL
have	NULL
reported	NULL
deletions	NULL
in	NULL
FHIT	NULL
transcripts	NULL
from	NULL
normal	NULL
tissues	NULL
,	NULL
but	NULL
characterised	NULL
these	NULL
as	NULL
different	NULL
from	NULL
deletions	NULL
present	NULL
in	NULL
tumours	NULL
(	NULL
Fong	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
;	NULL
Luan	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
we	NULL
saw	NULL
similar	NULL
types	NULL
of	NULL
deletions	NULL
in	NULL
both	NULL
tumour	NULL
and	NULL
normal	NULL
samples	NULL
.	NULL

In	NULL
all	NULL
cases	NULL
the	NULL
deletion	NULL
breakpoints	NULL
are	NULL
at	NULL
the	NULL
boundaries	NULL
of	NULL
exons	NULL
and	NULL
introns	NULL
(	NULL
see	NULL
Figure	NULL
3b	NULL
)	NULL
,	NULL
supporting	NULL
the	NULL
contention	NULL
that	NULL
they	NULL
probably	NULL
result	NULL
from	NULL
aberrant	NULL
splicing	NULL
.	NULL

Aberrant	NULL
splicing	NULL
has	NULL
been	NULL
previously	NULL
described	NULL
for	NULL
other	NULL
cancer-associated	NULL
genes	NULL
,	NULL
namely	NULL
p53	NULL
,	NULL
MLL	NULL
and	NULL
hMSH2	NULL
(	NULL
Flaman	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
;	NULL
Lochner	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
;	NULL
Nam	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
,	NULL
but	NULL
not	NULL
to	NULL
the	NULL
extent	NULL
that	NULL
we	NULL
are	NULL
now	NULL
reporting	NULL
for	NULL
TSGIO1	NULL
!	NULL

and	NULL
FHIT	NULL
.	NULL

One	NULL
possible	NULL
explanation	NULL
for	NULL
the	NULL
observations	NULL
in	NULL
TSGI01	NULL
!	NULL

and	NULL
FHIT	NULL
is	NULL
that	NULL
the	NULL
mechanisms	NULL
involved	NULL
in	NULL
the	NULL
control	NULL
of	NULL
RNA	NULL
splicing	NULL
have	NULL
been	NULL
disrupted	NULL
,	NULL
but	NULL
whatever	NULL
causes	NULL
this	NULL
disruption	NULL
appears	NULL
not	NULL
to	NULL
be	NULL
specific	NULL
for	NULL
cancer	NULL
cells	NULL
.	NULL

Importantly	NULL
,	NULL
mis-splicing	NULL
was	NULL
not	NULL
observed	NULL
in	NULL
normal	NULL
peripheral	NULL
blood	NULL
samples	NULL
in	NULL
seven	NULL
other	NULL
genes	NULL
,	NULL
BRCAL	NULL
!	NULL

,	NULL
BRCA2	NULL
,	NULL
BRUSH1	NULL
,	NULL
hMSH2	NULL
,	NULL
IGF2	NULL
receptor	NULL
,	NULL
PGDB	NULL
and	NULL
RB	NULL
,	NULL
indicating	NULL
that	NULL
this	NULL
is	NULL
not	NULL
a	NULL
generalized	NULL
phenom-enon	NULL
.	NULL

Lee	NULL
and	NULL
Feinberg	NULL
(	NULL
1997	NULL
)	NULL
in	NULL
their	NULL
report	NULL
quantitated	NULL
the	NULL
aberrant	NULL
TSG1O01	NULL
transcripts	NULL
and	NULL
showed	NULL
that	NULL
in	NULL
cancer	NULL
cells	NULL
they	NULL
represent	NULL
a	NULL
large	NULL
percentage	NULL
of	NULL
the	NULL
RT-PCR	NULL
products	NULL
and	NULL
in	NULL
normal	NULL
cells	NULL
3-4	NULL
%	NULL
of	NULL
RNA	NULL
.	NULL

It	NULL
seems	NULL
therefore	NULL
unlikely	NULL
that	NULL
the	NULL
aberrant	NULL
transcripts	NULL
are	NULL
the	NULL
result	NULL
of	NULL
some	NULL
experimental	NULL
artefact	NULL
.	NULL

In	NULL
conclusion	NULL
,	NULL
these	NULL
data	NULL
strongly	NULL
suggest	NULL
that	NULL
most	NULL
of	NULL
the	NULL
truncations	NULL
observed	NULL
in	NULL
TSGIO1	NULL
and	NULL
FHIT	NULL
transcripts	NULL
result	NULL
from	NULL
alternative	NULL
and	NULL
aberrant	NULL
splicing	NULL
events	NULL
.	NULL

It	NULL
remains	NULL
to	NULL
be	NULL
seen	NULL
whether	NULL
truncated	NULL
TSGIO1	NULL
and	NULL
FHIT	NULL
transcripts	NULL
are	NULL
important	NULL
in	NULL
tumour	NULL
progression	NULL
in	NULL
a	NULL
wide	NULL
variety	NULL
of	NULL
malignancies	NULL
or	NULL
whether	NULL
these	NULL
truncations	NULL
are	NULL
merely	NULL
the	NULL
consequence	NULL
of	NULL
altered	NULL
mRNA	NULL
splicing	NULL
fidelity	NULL
that	NULL
occurs	NULL
more	NULL
commonly	NULL
in	NULL
tumour	NULL
cells	NULL
.	NULL

In	NULL
the	NULL
case	NULL
of	NULL
FHIT	NULL
,	NULL
FISH	NULL
and	NULL
Southern	NULL
blot	NULL
analysis	NULL
have	NULL
shown	NULL
that	NULL
in	NULL
some	NULL
tumours	NULL
and	NULL
cell	NULL
lines	NULL
the	NULL
same	NULL
exons	NULL
that	NULL
are	NULL
missing	NULL
from	NULL
the	NULL
truncated	NULL
transcripts	NULL
appear	NULL
to	NULL
be	NULL
deleted	NULL
in	NULL
genomic	NULL
DNA	NULL
(	NULL
Druck	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
;	NULL
Virgilio	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
.	NULL

Despite	NULL
this	NULL
,	NULL
it	NULL
has	NULL
not	NULL
been	NULL
possible	NULL
to	NULL
clone	NULL
any	NULL
of	NULL
the	NULL
putative	NULL
genomic	NULL
breakpoints	NULL
and	NULL
so	NULL
the	NULL
evidence	NULL
that	NULL
FHIT	NULL
is	NULL
the	NULL
real	NULL
target	NULL
of	NULL
the	NULL
genomic	NULL
deletions	NULL
seen	NULL
at	NULL
the	NULL
fragile	NULL
site	NULL
locus	NULL
that	NULL
encompasses	NULL
this	NULL
gene	NULL
is	NULL
lacking	NULL
.	NULL

A	NULL
similar	NULL
scenario	NULL
appears	NULL
to	NULL
be	NULL
emerging	NULL
for	NULL
TSGIO1	NULL
;	NULL
a	NULL
variety	NULL
of	NULL
transcript	NULL
deletions	NULL
are	NULL
frequently	NULL
detected	NULL
but	NULL
as	NULL
yet	NULL
there	NULL
is	NULL
no	NULL
direct	NULL
evidence	NULL
that	NULL
genomic	NULL
deletions	NULL
correspond	NULL
to	NULL
these	NULL
aberrant	NULL
transcripts	NULL
.	NULL

Materials	NULL
and	NULL
methods	NULL
Patient	NULL
material	NULL
and	NULL
cancer	NULL
cell	NULL
lines	NULL
EBV-transformed	NULL
B-cells	NULL
were	NULL
derived	NULL
from	NULL
individuals	NULL
(	NULL
both	NULL
affected	NULL
and	NULL
unaffected	NULL
)	NULL
from	NULL
breast	NULL
and	NULL
ovarian	NULL
cancer	NULL
families	NULL
.	NULL

All	NULL
tissue	NULL
samples	NULL
were	NULL
snap	NULL
frozen	NULL
upon	NULL
collection	NULL
and	NULL
stored	NULL
at	NULL
-80°C	NULL
;	NULL
cancer	NULL
cell	NULL
lines	NULL
and	NULL
EBV	NULL
transformed	NULL
lymphocytes	NULL
were	NULL
grown	NULL
to	NULL
confluence	NULL
;	NULL
peripheral	NULL
blood	NULL
samples	NULL
drawn	NULL
from	NULL
12	NULL
healthy	NULL
individuals	NULL
were	NULL
collected	NULL
in	NULL
EDTA	NULL
.	NULL

The	NULL
names	NULL
of	NULL
cell	NULL
lines	NULL
obtained	NULL
commercially	NULL
(	NULL
breast	NULL
,	NULL
ovarian	NULL
and	NULL
lung	NULL
cancer	NULL
)	NULL
and	NULL
used	NULL
in	NULL
this	NULL
study	NULL
are	NULL
available	NULL
on	NULL
request	NULL
(	NULL
email	NULL
:	NULL
sg200	NULL
@	NULL
cam.ac.uk	NULL
)	NULL
RNA	NULL
extraction	NULL
Total	NULL
RNA	NULL
extraction	NULL
was	NULL
performed	NULL
using	NULL
either	NULL
TRIzol	NULL
``	NULL
``	NULL
(	NULL
Life	NULL
Technologies	NULL
)	NULL
or	NULL
Purescript	NULL
'	NULL
``	NULL
(	NULL
Gentra	NULL
Systems	NULL
,	NULL
Inc.	NULL
)	NULL
in	NULL
primary	NULL
ovarian	NULL
,	NULL
breast	NULL
and	NULL
non-small	NULL
cell	NULL
lung	NULL
cancers	NULL
,	NULL
ovarian	NULL
,	NULL
breast	NULL
and	NULL
lung	NULL
cancer	NULL
cell	NULL
lines	NULL
,	NULL
low-passage	NULL
melanoma	NULL
cell	NULL
lines	NULL
,	NULL
chronic	NULL
lymphocytic	NULL
leukaemias	NULL
(	NULL
CLL	NULL
)	NULL
,	NULL
EBV-immortalized	NULL
cell	NULL
lines	NULL
and	NULL
normal	NULL
lung	NULL
parenchyma	NULL
.	NULL

For	NULL
peripheral	NULL
blood	NULL
samples	NULL
,	NULL
RNA	NULL
extraction	NULL
was	NULL
performed	NULL
immediately	NULL
from	NULL
half	NULL
of	NULL
each	NULL
10	NULL
ml	NULL
sample	NULL
and	NULL
following	NULL
separation	NULL
of	NULL
white	NULL
blood	NULL
cells	NULL
through	NULL
a	NULL
ficoll	NULL
gradient	NULL
;	NULL
the	NULL
remainder	NULL
of	NULL
each	NULL
sample	NULL
was	NULL
incubated	NULL
at	NULL
room	NULL
temperature	NULL
for	NULL
60	NULL
h	NULL
prior	NULL
to	NULL
RNA	NULL
extraction	NULL
.	NULL

DNA	NULL
extraction	NULL
Forty-seven	NULL
tumours	NULL
for	NULL
which	NULL
a	NULL
matching	NULL
blood	NULL
sample	NULL
was	NULL
available	NULL
were	NULL
sectioned	NULL
and	NULL
micro-dissected	NULL
to	NULL
minimise	NULL
contaminating	NULL
normal	NULL
tissue	NULL
;	NULL
DNA	NULL
extraction	NULL
was	NULL
performed	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
Foster	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
.	NULL

DNA	NULL
was	NULL
extracted	NULL
from	NULL
some	NULL
cell	NULL
lines	NULL
and	NULL
CLL	NULL
samples	NULL
using	NULL
Puregene	NULL
``	NULL
``	NULL
``	NULL
(	NULL
Gentra	NULL
Systems	NULL
,	NULL
Inc.	NULL
)	NULL
TSG101	NULL
analysis	NULL
All	NULL
primers	NULL
used	NULL
for	NULL
TSGIO1	NULL
!	NULL

analysis	NULL
are	NULL
available	NULL
on	NULL
request	NULL
(	NULL
email	NULL
:	NULL
sg200	NULL
@	NULL
cam.ac.uk	NULL
)	NULL
Analysis	NULL
of	NULL
mRNA	NULL
transcripts	NULL
All	NULL
analyses	NULL
of	NULL
mRNA	NULL
transcripts	NULL
were	NULL
performed	NULL
using	NULL
cDNA	NULL
reverse	NULL
transcribed	NULL
from	NULL
RNA	NULL
by	NULL
either	NULL
oligo	NULL
dT	NULL
(	NULL
15	NULL
)	NULL
or	NULL
random	NULL
hexamer	NULL
priming	NULL
.	NULL

All	NULL
RT	NULL
reactions	NULL
included	NULL
a	NULL
tube	NULL
with	NULL
no	NULL
added	NULL
RT	NULL
as	NULL
a	NULL
negative	NULL
control	NULL
.	NULL

Primers	NULL
located	NULL
in	NULL
5	NULL
and	NULL
3	NULL
'	NULL
untranslated	NULL
sequences	NULL
were	NULL
used	NULL
to	NULL
amplify	NULL
the	NULL
entire	NULL
coding	NULL
region	NULL
of	NULL
TSGI01	NULL
using	NULL
single	NULL
round	NULL
(	NULL
35-40	NULL
cycles	NULL
)	NULL
or	NULL
nested	NULL
PCR	NULL
(	NULL
15-20	NULL
cycles	NULL
)	NULL
and	NULL
size	NULL
fractionated	NULL
by	NULL
agarose	NULL
gel	NULL
electrophoresis	NULL
.	NULL

Primers	NULL
used	NULL
for	NULL
nested	NULL
PCR	NULL
were	NULL
the	NULL
same	NULL
as	NULL
those	NULL
used	NULL
for	NULL
the	NULL
PTT	NULL
assay	NULL
.	NULL

Amplification	NULL
reactions	NULL
(	NULL
30	NULL
ul	NULL
)	NULL
contained	NULL
20	NULL
mm	NULL
(	NULL
NH4	NULL
)	NULL
,	NULL
SO	NULL
.	NULL

,	NULL
,	NULL
75	NULL
mm	NULL
Tris-HCI	NULL
,	NULL
pH	NULL
9.0	NULL
at	NULL
25°C	NULL
,	NULL
0.1	NULL
%	NULL
(	NULL
w/v	NULL
)	NULL
Tween	NULL
,	NULL
1.5	NULL
mm	NULL
MgCl	NULL
,	NULL
200	NULL
um	NULL
each	NULL
dATP	NULL
,	NULL
dCTP	NULL
,	NULL
dGTP	NULL
and	NULL
dTTP	NULL
,	NULL
20	NULL
picomoles	NULL
of	NULL
each	NULL
primer	NULL
,	NULL
and	NULL
2.5	NULL
units	NULL
of	NULL
Red	NULL
Hot	NULL
DNA	NULL
polymerase	NULL
(	NULL
Advanced	NULL
Biotechnologies	NULL
)	NULL
.	NULL

All	NULL
PCR	NULL
experiments	NULL
were	NULL
done	NULL
with	NULL
a	NULL
template-negative	NULL
tube	NULL
as	NULL
control	NULL
.	NULL

PCR	NULL
fragments	NULL
were	NULL
purified	NULL
from	NULL
2	NULL
%	NULL
low	NULL
melting	NULL
point	NULL
(	NULL
LMP	NULL
)	NULL
agarose	NULL
and	NULL
reamplified	NULL
for	NULL
direct	NULL
sequencing	NULL
.	NULL

Sequence	NULL
analysis	NULL
was	NULL
performed	NULL
using	NULL
the	NULL
ABI	NULL
373	NULL
semi-automated	NULL
DNA	NULL
sequencer	NULL
and	NULL
dye	NULL
terminator	NULL
cycle	NULL
sequencing	NULL
with	NULL
AmpliTaq	NULL
DNA	NULL
polymerase	NULL
,	NULL
FS	NULL
(	NULL
Perkin	NULL
Elmer	NULL
)	NULL
.	NULL

The	NULL
protein	NULL
truncation	NULL
test	NULL
(	NULL
PTT	NULL
)	NULL
was	NULL
performed	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
Gayther	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
using	NULL
a	NULL
sense	NULL
primer	NULL
incorporating	NULL
a	NULL
T7	NULL
promoter	NULL
sequence	NULL
.	NULL

Single	NULL
strand	NULL
Aberrant	NULL
splicing	NULL
of	NULL
TSG101	NULL
and	NULL
FHIT	NULL
SA	NULL
Gayther	NULL
et	NULL
al	NULL
conformation	NULL
analysis	NULL
analysis	NULL
(	NULL
SSCA/HA	NULL
)	NULL
was	NULL
performed	NULL
using	NULL
MDE	NULL
(	NULL
Flowgen	NULL
)	NULL
polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
Gayther	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
.	NULL

Analysis	NULL
of	NULL
genomic	NULL
DNA	NULL
Oligonucleotide	NULL
primers	NULL
located	NULL
within	NULL
exons	NULL
1	NULL
and	NULL
5	NULL
and	NULL
flanking	NULL
the	NULL
breakpoints	NULL
of	NULL
three	NULL
TSGIO	NULL
!	NULL

transcript	NULL
deletions	NULL
(	NULL
nucl	NULL
.	NULL

568-1113	NULL
(	NULL
568	NULL
bp	NULL
)	NULL
;	NULL
133-730	NULL
(	NULL
598	NULL
bp	NULL
)	NULL
;	NULL
154-1054	NULL
(	NULL
901	NULL
bp	NULL
)	NULL
)	NULL
were	NULL
used	NULL
to	NULL
try	NULL
to	NULL
amplify	NULL
the	NULL
products	NULL
of	NULL
the	NULL
deletions	NULL
from	NULL
genomic	NULL
DNA	NULL
of	NULL
primary	NULL
tumours	NULL
,	NULL
cancer	NULL
cell	NULL
lines	NULL
and	NULL
normal	NULL
tissue	NULL
.	NULL

PCR-Southern	NULL
blot	NULL
analysis	NULL
was	NULL
performed	NULL
using	NULL
genomic	NULL
DNA	NULL
from	NULL
47	NULL
ovarian	NULL
tumours	NULL
and	NULL
matching	NULL
blood	NULL
samples	NULL
,	NULL
five	NULL
breast	NULL
and	NULL
ovarian	NULL
cancer	NULL
cell	NULL
lines	NULL
and	NULL
from	NULL
four	NULL
CLL	NULL
samples	NULL
.	NULL

Nested	NULL
PCR	NULL
using	NULL
pairs	NULL
of	NULL
primers	NULL
located	NULL
in	NULL
exonic	NULL
and	NULL
intronic	NULL
sequences	NULL
and	NULL
which	NULL
flank	NULL
the	NULL
breakpoints	NULL
of	NULL
all	NULL
the	NULL
deletions	NULL
we	NULL
detected	NULL
,	NULL
were	NULL
used	NULL
to	NULL
try	NULL
to	NULL
amplify	NULL
fragments	NULL
between	NULL
exon	NULL
1	NULL
and	NULL
exon	NULL
5	NULL
.	NULL

PCR	NULL
products	NULL
were	NULL
Southern	NULL
blotted	NULL
(	NULL
Hybond	NULL
N*	NULL
,	NULL
Amersham	NULL
)	NULL
and	NULL
hybridized	NULL
with	NULL
a	NULL
P-labelled	NULL
full	NULL
length	NULL
cDNA	NULL
probe	NULL
.	NULL

Fragments	NULL
which	NULL
hybridized	NULL
to	NULL
TSG101	NULL
were	NULL
purified	NULL
from	NULL
2	NULL
%	NULL
LMP	NULL
agarose	NULL
gels	NULL
,	NULL
cloned	NULL
using	NULL
the	NULL
TA	NULL
cloning	NULL
system	NULL
(	NULL
Invitrogen	NULL
)	NULL
and	NULL
sequenced	NULL
as	NULL
described	NULL
above	NULL
.	NULL

Southern	NULL
blot	NULL
hybridization	NULL
was	NULL
performed	NULL
using	NULL
genomic	NULL
DNA	NULL
from	NULL
19	NULL
primary	NULL
ovarian	NULL
tumours	NULL
digested	NULL
with	NULL
EcoRI	NULL
and	NULL
from	NULL
six	NULL
ovarian	NULL
and	NULL
lung	NULL
cancer	NULL
cell	NULL
lines	NULL
digested	NULL
with	NULL
EcoRI	NULL
,	NULL
BamHI	NULL
and	NULL
HindIII	NULL
.	NULL

Between	NULL
5	NULL
and	NULL
10	NULL
ug	NULL
of	NULL
DNA	NULL
were	NULL
digested	NULL
overnight	NULL
prior	NULL
to	NULL
Southern	NULL
blotting	NULL
and	NULL
hybridization	NULL
with	NULL
a	NULL
full	NULL
length	NULL
cDNA	NULL
probe	NULL
.	NULL

SSCA/HA	NULL
was	NULL
used	NULL
to	NULL
screen	NULL
all	NULL
six	NULL
coding	NULL
exons	NULL
of	NULL
TSGIO1	NULL
from	NULL
genomic	NULL
DNA	NULL
from	NULL
47	NULL
sporadic	NULL
ovarian	NULL
tumour-blood	NULL
pairs	NULL
,	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
Gayther	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
.	NULL

Analysis	NULL
of	NULL
mRNA	NULL
transcripts	NULL
from	NULL
multiple	NULL
genes	NULL
in	NULL
normal	NULL
peripheral	NULL
blood	NULL
cDNA	NULL
reverse	NULL
transcribed	NULL
from	NULL
RNA	NULL
isolated	NULL
from	NULL
fresh	NULL
and	NULL
incubated	NULL
blood	NULL
samples	NULL
from	NULL
12	NULL
healthy	NULL
individuals	NULL
(	NULL
see	NULL
above	NULL
)	NULL
was	NULL
used	NULL
to	NULL
amplify	NULL
partial	NULL
or	NULL
complete	NULL
transcripts	NULL
from	NULL
BRCA	NULL
!	NULL

(	NULL
exons	NULL
17-22	NULL
)	NULL
,	NULL
BRCA2	NULL
(	NULL
exons	NULL
3-10	NULL
)	NULL
,	NULL
BRUSHI	NULL
,	NULL
FHIT	NULL
,	NULL
IGF2	NULL
receptor	NULL
,	NULL
PGDB	NULL
,	NULL
TSG101	NULL
,	NULL
hMSH2	NULL
and	NULL
RB	NULL
.	NULL

TSG101	NULL
analysis	NULL
is	NULL
described	NULL
above	NULL
.	NULL

The	NULL
primers	NULL
used	NULL
for	NULL
FHIT	NULL
analysis	NULL
have	NULL
been	NULL
described	NULL
previously	NULL
.	NULL

BRCAI	NULL
,	NULL
BRCA2	NULL
,	NULL
hMSH2	NULL
,	NULL
TSG101	NULL
and	NULL
FHIT	NULL
were	NULL
analysed	NULL
using	NULL
nested	NULL
PCR	NULL
;	NULL
BRUSH	NULL
1	NULL
,	NULL
IGF2	NULL
receptor	NULL
,	NULL
PGDB	NULL
,	NULL
and	NULL
RB	NULL
were	NULL
amplified	NULL
using	NULL
a	NULL
single	NULL
round	NULL
of	NULL
PCR	NULL
.	NULL

All	NULL
primer	NULL
sequences	NULL
are	NULL
available	NULL
on	NULL
request	NULL
(	NULL
email	NULL
:	NULL
sg200	NULL
@	NULL
cam.ac.uk	NULL
)	NULL
.	NULL

FHIT	NULL
was	NULL
analysed	NULL
also	NULL
for	NULL
intragenic	NULL
deletions	NULL
in	NULL
RNA	NULL
from	NULL
primary	NULL
tumours	NULL
and/or	NULL
cell	NULL
lines	NULL
from	NULL
ovarian	NULL
,	NULL
breast	NULL
and	NULL
lung	NULL
cancers	NULL
,	NULL
melanomas	NULL
and	NULL
chronic	NULL
lymphocytic	NULL
leukaemias	NULL
(	NULL
CLL	NULL
)	NULL
,	NULL
from	NULL
EBV-immortalized	NULL
B-cells	NULL
and	NULL
normal	NULL
lung	NULL
parenchyma	NULL
(	NULL
Tables	NULL
3	NULL
and	NULL
4	NULL
)	NULL
.	NULL

Acknowledgements	NULL
This	NULL
research	NULL
was	NULL
supported	NULL
by	NULL
the	NULL
Cancer	NULL
Research	NULL
Campaign	NULL
[	NULL
CRC	NULL
]	NULL
.	NULL

We	NULL
thank	NULL
Ian	NULL
V	NULL
Scott	NULL
,	NULL
Jo	NULL
Dearden	NULL
,	NULL
Carole	NULL
Pye	NULL
,	NULL
Samantha	NULL
Crockett	NULL
and	NULL
Anne	NULL
Wilson	NULL
for	NULL
help	NULL
with	NULL
collection	NULL
and	NULL
preparation	NULL
of	NULL
samples	NULL
and	NULL
Paul	NULL
Russell	NULL
for	NULL
technical	NULL
assistance	NULL
.	NULL

We	NULL
wish	NULL
to	NULL
thank	NULL
Jorge	NULL
Soares	NULL
,	NULL
Mark	NULL
Crompton	NULL
,	NULL
Pam	NULL
Rabbitts	NULL
and	NULL
Jose	NULL
Garcia-Marco	NULL
for	NULL
some	NULL
of	NULL
the	NULL
tumour	NULL
samples	NULL
and	NULL
cell	NULL
lines	NULL
used	NULL
in	NULL
this	NULL
study	NULL
.	NULL

PB	NULL
was	NULL
supported	NULL
by	NULL
an	NULL
Individual	NULL
Mobility	NULL
Grant	NULL
provided	NULL
by	NULL
Tempus-Phare	NULL
.	NULL

KF	NULL
is	NULL
supported	NULL
by	NULL
the	NULL
Overseas	NULL
Research	NULL
Student	NULL
Award	NULL
Scheme	NULL
and	NULL
the	NULL
National	NULL
Science	NULL
Foundation	NULL
Graduate	NULL
Fellowship	NULL
Pro-gram	NULL
.	NULL

BAJP	NULL
is	NULL
a	NULL
Gibb	NULL
Fellow	NULL
of	NULL
the	NULL
CRC	NULL
.	NULL

2125	NULL
Aberrant	NULL
splicing	NULL
of	NULL
TSG101	NULL
and	NULL
FHIT	NULL
SA	NULL
Gayther	NULL
et	NULL
al	NULL
2126	NULL
References	NULL
Druck	NULL
T	NULL
,	NULL
Hadaczek	NULL
P	NULL
,	NULL
Fu	NULL
T-B	NULL
,	NULL
Ohta	NULL
M	NULL
,	NULL
Siprashvili	NULL
Z	NULL
,	NULL
Baffa	NULL
R	NULL
,	NULL
Negrin	NULL
M	NULL
,	NULL
Kastury	NULL
K	NULL
,	NULL
Veronese	NULL
ML	NULL
,	NULL
Rosen	NULL
D	NULL
,	NULL
Rothstein	NULL
J	NULL
,	NULL
McCue	NULL
P	NULL
,	NULL
Cotticelli	NULL
MG	NULL
,	NULL
Inoue	NULL
H	NULL
,	NULL
Croce	NULL
CM	NULL
and	NULL
Huebner	NULL
K.	NULL
(	NULL
1997	NULL
)	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
57	NULL
,	NULL
504-512	NULL
.	NULL

Flaman	NULL
J-M	NULL
,	NULL
Waridel	NULL
F	NULL
,	NULL
Estreicher	NULL
A	NULL
,	NULL
Vannier	NULL
A	NULL
,	NULL
Limacher	NULL
J-M	NULL
,	NULL
Gilbert	NULL
D	NULL
,	NULL
Iggo	NULL
R	NULL
and	NULL
Frebourg	NULL
T.	NULL
(	NULL
1996	NULL
)	NULL
.	NULL

Oncogene	NULL
,	NULL
12	NULL
,	NULL
813-818	NULL
.	NULL

Fong	NULL
KM	NULL
,	NULL
Biesterveld	NULL
EJ	NULL
,	NULL
Virmani	NULL
A	NULL
,	NULL
Wistuba	NULL
I	NULL
,	NULL
Sekido	NULL
Y	NULL
,	NULL
Bader	NULL
SA	NULL
,	NULL
Ahmadian	NULL
M	NULL
,	NULL
Ong	NULL
ST	NULL
,	NULL
Rassool	NULL
FY	NULL
,	NULL
Zimmerman	NULL
PV	NULL
,	NULL
Giaccone	NULL
G	NULL
,	NULL
Gazdar	NULL
AF	NULL
and	NULL
Minna	NULL
JD	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
57	NULL
,	NULL
2256-2267	NULL
.	NULL

Foster	NULL
KA	NULL
,	NULL
Harrington	NULL
PA	NULL
,	NULL
Kerr	NULL
J	NULL
,	NULL
Russell	NULL
PA	NULL
,	NULL
DiCiocco	NULL
RA	NULL
,	NULL
Scott	NULL
IV	NULL
,	NULL
Jacobs	NULL
I	NULL
,	NULL
Chenevix-Trench	NULL
G	NULL
,	NULL
Ponder	NULL
BAJ	NULL
and	NULL
Gayther	NULL
SA	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
56	NULL
,	NULL
3622-3625	NULL
.	NULL

Gayther	NULL
SA	NULL
,	NULL
Mangion	NULL
J	NULL
,	NULL
Russell	NULL
P	NULL
,	NULL
Seal	NULL
S	NULL
,	NULL
Barfoot	NULL
R	NULL
,	NULL
Ponder	NULL
BAJ	NULL
,	NULL
Stratton	NULL
M	NULL
and	NULL
Easton	NULL
D.	NULL
(	NULL
1997	NULL
)	NULL
.	NULL

Nature	NULL
Genetics	NULL
,	NULL
15	NULL
,	NULL
103-105	NULL
.	NULL

Hayashi	NULL
S-I	NULL
,	NULL
Tanimoto	NULL
K	NULL
,	NULL
Hajiro-Nakanishi	NULL
K	NULL
,	NULL
Tsuchiya	NULL
E	NULL
,	NULL
Kurosumi	NULL
M	NULL
,	NULL
Higashi	NULL
Y	NULL
,	NULL
Imai	NULL
K	NULL
,	NULL
Suga	NULL
K	NULL
and	NULL
Nakachi	NULL
K.	NULL
(	NULL
1997	NULL
)	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
57	NULL
,	NULL
1981-1985	NULL
.	NULL

Huebner	NULL
K	NULL
,	NULL
Hadaczek	NULL
P	NULL
,	NULL
Siprashvili	NULL
Z	NULL
,	NULL
Druck	NULL
T	NULL
and	NULL
Croce	NULL
CM	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
.	NULL

Biochim	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
,	NULL
1332	NULL
,	NULL
M65-M70	NULL
.	NULL

Lee	NULL
MP	NULL
and	NULL
Feinberg	NULL
AP	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
57	NULL
,	NULL
3131	NULL
3134	NULL
.	NULL

Li	NULL
L	NULL
and	NULL
Cohen	NULL
SN	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
.	NULL

Cell	NULL
,	NULL
85	NULL
,	NULL
319-329	NULL
.	NULL

Li	NULL
L	NULL
,	NULL
Li	NULL
X	NULL
,	NULL
Francke	NULL
U	NULL
and	NULL
Cohen	NULL
SN	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
.	NULL

Cell	NULL
,	NULL
88	NULL
,	NULL
143	NULL
154	NULL
.	NULL

Locher	NULL
K	NULL
,	NULL
Siegler	NULL
G	NULL
,	NULL
Fuhrer	NULL
M	NULL
,	NULL
Greil	NULL
J	NULL
,	NULL
Beck	NULL
JD	NULL
,	NULL
Fey	NULL
GH	NULL
and	NULL
Marschalek	NULL
R.	NULL
(	NULL
1996	NULL
)	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
56	NULL
,	NULL
2171-2177	NULL
.	NULL

Luan	NULL
X	NULL
,	NULL
Shi	NULL
G	NULL
,	NULL
Zohouri	NULL
M	NULL
,	NULL
Paradee	NULL
W	NULL
,	NULL
Smith	NULL
DI	NULL
,	NULL
Decker	NULL
HJ	NULL
and	NULL
Cannizzaro	NULL
LA	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
.	NULL

Oncogene	NULL
,	NULL
15	NULL
,	NULL
79-86	NULL
.	NULL

Nam	NULL
DK	NULL
,	NULL
Honoki	NULL
K	NULL
,	NULL
Yu	NULL
M	NULL
and	NULL
Yunis	NULL
JJ	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
.	NULL

Gene	NULL
,	NULL
178	NULL
,	NULL
169-175	NULL
.	NULL

Ohta	NULL
M	NULL
,	NULL
Inoue	NULL
H	NULL
,	NULL
Cotticelli	NULL
MG	NULL
,	NULL
Kastury	NULL
K	NULL
,	NULL
Baffa	NULL
R	NULL
,	NULL
Palazzo	NULL
J	NULL
,	NULL
Siprashvili	NULL
Z	NULL
,	NULL
Mori	NULL
M	NULL
,	NULL
McCue	NULL
P	NULL
,	NULL
Druck	NULL
T	NULL
,	NULL
Croce	NULL
CM	NULL
and	NULL
Huebner	NULL
K.	NULL
(	NULL
1996	NULL
)	NULL
.	NULL

Cell	NULL
,	NULL
84	NULL
,	NULL
587-597	NULL
.	NULL

Sozzi	NULL
G	NULL
,	NULL
Veronese	NULL
ML	NULL
,	NULL
Negrini	NULL
M	NULL
,	NULL
Baffa	NULL
R	NULL
,	NULL
Cotticelli	NULL
MG	NULL
,	NULL
Inoue	NULL
H	NULL
,	NULL
Tornielli	NULL
S	NULL
,	NULL
Pilotti	NULL
S	NULL
,	NULL
De	NULL
Gregorio	NULL
L	NULL
,	NULL
Pastorino	NULL
U	NULL
,	NULL
Pierotti	NULL
MA	NULL
,	NULL
Ohta	NULL
M	NULL
,	NULL
Huebner	NULL
K	NULL
and	NULL
Croce	NULL
CM	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
.	NULL

Cell	NULL
,	NULL
85	NULL
,	NULL
17-26	NULL
.	NULL

Steiner	NULL
P	NULL
,	NULL
Barnes	NULL
DM	NULL
,	NULL
Harris	NULL
WH	NULL
and	NULL
Weinberg	NULL
RA	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
.	NULL

Nature	NULL
Genetics	NULL
,	NULL
16	NULL
,	NULL
332-333	NULL
.	NULL

Virgilio	NULL
L	NULL
,	NULL
Shuster	NULL
M	NULL
,	NULL
Gollin	NULL
SM	NULL
,	NULL
Veronese	NULL
ML	NULL
,	NULL
Ohta	NULL
M	NULL
,	NULL
Huebner	NULL
K	NULL
and	NULL
Croce	NULL
CM	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Nat	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
93	NULL
,	NULL
9770-9775	NULL
.	NULL

